PERSONAL HISTORY Work Pfleger Liver Institute Suite 214 ...
Transcript of PERSONAL HISTORY Work Pfleger Liver Institute Suite 214 ...
Updated 4/2020
Saab 1
CURRICULUM VITAE
Saab, Sammy, MD, MPH
PERSONAL HISTORY
Work Pfleger Liver Institute
200 UCLA Medical Plaza
Suite 214
Los Angeles, CA 90095-7302
Tel: 310-206-6705, Fax: 310-206-4197
EDUCATION
1985 - 1989 Bachelor of Science ~ Psychobiology
University of California at Los Angeles
1989 - 1993 Doctor of Medicine
University of California at Los Angeles
1993 - 1996 Internship and Residency ~ Internal Medicine
University of California at San Diego, Medical Center
1996 - 1997 Chief Medical Resident
University of California at San Diego, Medical Center
1997 - 2000 Fellowship ~ Gastroenterology/Hepatology
University of California at Los Angeles, Center for Health Sciences
1999 - 2001 Master of Public Health ~ Epidemiology
University of California at Los Angeles
LICENSURE
State, Certificate Number CA, GO80181
BOARD CERTIFICATION
Eligible American Board of Internal Medicine
Active Gastroenterology
Active Drug Enforcement Agency
Active Certification in Transplant Hepatology
PROFESSIONAL EXPERIENCE
Current
2012 - present Professor of Clinical Medicine
Division of Digestive Diseases, Department of Internal Medicine and
Dumont-UCLA Liver Transplantation, Department of Surgery
University of California at Los Angeles, Center for Health Sciences
Saab 2
Previous
1995 - 1997 Volunteer Physician
Saint Vincent DePaul Homeless Shelter, San Diego, California
1996 - 1997 Clinical Instructor, Department of Internal Medicine
University of California at San Diego, Medical Center
2000 - 2002 Clinical Instructor
Division of Digestive Diseases, Department of Internal Medicine
University of California at Los Angeles, Center for Health Sciences
2001 - 2002 Clinical Instructor
Dumont-UCLA Liver Transplantation, Department of Surgery
University of California at Los Angeles, Center for Health Sciences
2002 - 2006 Assistant Clinical Professor (Comp)
Division of Digestive Diseases, Department of Internal Medicine and
Dumont-UCLA Liver Transplantation, Department of Surgery
University of California at Los Angeles, Center for Health Sciences
2006 - 2008 Associate Clinical Professor (Comp)
Division of Digestive Diseases, Department of Internal Medicine and
Dumont-UCLA Liver Transplantation, Department of Surgery
University of California at Los Angeles, Center for Health Sciences
2007 - present Head, Outcomes Research in Hepatology
Pfleger Liver Institute, University of California at Los Angeles
2008 - 2012 Associate Professor of Clinical Medicine
Division of Digestive Diseases, Department of Internal Medicine and
Dumont-UCLA Liver Transplantation, Department of Surgery
University of California at Los Angeles, Center for Health Sciences
2010 - present Adjunct Professor
School of Nursing, University of California at Los Angeles
2012 - present Professor of Clinical Medicine (X)
Division of Digestive Diseases, Department of Internal Medicine and
Dumont-UCLA Liver Transplantation, Department of Surgery
University of California at Los Angeles, Center for Health Sciences
2020 Medical Director, Adult Liver Transplant, Dumont-UCLA Liver
Transplantation, Department of Surgery, University of California at Los
Angeles, Center for Health Sciences
2020 Chief, Hepatology, Department of Internal Medicine and Dumont-UCLA
Liver Transplantation, Department of Surgery University of California at
Los Angeles, Center for Health Sciences
Saab 3
2020 Director, Pfleger Liver Institute, University of California at Los Angeles,
Center for Health Sciences
PROFESSIONAL AFFILIATIONS
American Association for the Study of Liver Disease
American College of Gastroenterology
American Gastroenterological Association
American Society of Transplantation
Italian Society of Surgical Research- Societa' Italiana di Ricerche in
Chirurgia, honorary member
PROFESSIONAL ACTIVITIES
Local
2001 - present American Liver Foundation, Los Angeles Chapter
Medical Advisory Committee
2001 - 2014 University of California Los Angeles, Department of Medicine
Residency Selection Committee
2001 - present University of California Los Angeles, Department of Surgery
Multidisciplinary Patient Selection Committee for Liver Transplantation
2005 - present University of California Los Angeles, Division of Transplantation
Liver Transplant Executive Committee
2005 - 2014 Ventura County/West Valley Chapter of TRIO
Medical Advisory Committee
2006 - 2014 University of California Los Angeles, Department of Medicine
Morbidity and Mortality Committee
National/International
2004 – 2007 Educational Committee
American Association for the Study of Liver Diseases
2004 - 2007 Liver and Intestines Committee
American Society of Transplantation
2006 - 2008 Practice Guidelines Committee
American Society of Transplantation
2006 Review Committee for Internal Medicine, Pre-reviewer for Liver
Transplantation, Accreditation Council for Graduate Medical Education
2005 International Liver Transplantation Society
Abstract chair, Recurrent Disease and Infectious Disease
2008 - 2014 Board of Appeals Panel for Transplant Hepatology
Accreditation Council for Graduate Medical Education
2008 - 2017 Abstract Reviewer - Health Services Research: Health Care
Delivery/Quality/Effectiveness - Access to Care; Economics of Care.
American Association for the Study of Liver Diseases
2010 Abstract Reviewer – Recurrent Diseases. American Transplant Congress
2011 - 2014 Journals Publications Committee. American Association for the Study of
Liver Diseases
Saab 4
2018 Abstract Review Chair Reviewer - Health Services Research: Health Care
Delivery/Quality/Effectiveness - Access to Care; Economics of Care.
American Association for the Study of Liver Diseases
2019 Abstract Review Chair Reviewer - Health Services Research: Health Care
Delivery/Quality/Effectiveness - Access to Care; Economics of Care.
American Association for the Study of Liver Diseases:
Saab 5
HONORS/AWARDS
1990 Pacific Basin Scholarship
1991 Psychiatry Summer Research Fellowship
1993 Merck Book Award
1999 AGA/Wyeth-Ayerst Resident and Fellows Reporter Award
1999 Gastroenterology Fellow of the Year, University of California Los
Angeles
2000 Cochrane Hepato-Biliary Group Award for Systematic Review
2000 American Society of Transplantation Travel Award
2000 AASLD/Schering Advanced Hepatology Fellowship Award
2000 American College of Gastroenterology Clinical Research Award
2005 Outstanding Reviewer Award, American Journal of Gastroenterology
2006 Outstanding Reviewer Award, American Journal of Gastroenterology
2008 Fellow, American Gastroenterology Association
2008 Distinguished Achievement Award, Division of Digestive Diseases
2009 Visiting Lecturer, Kansas University Medical Center, Kansas City
2009 Visiting Lecturer, John Hopkins Hospital, Baltimore
2010 Visiting Lecturer, Beth-Israel Deaconess Medical Center, Boston
2010 Visiting Lecturer, Brooke Army Medical Center, San Antonio, Texas
2010 Visiting Lecturer, Albert Einstein Medical Center, Philadelphia,
Pennsylvania
2013 Visiting Lecturer, Carolinas Healthcare Medical Center, Charlotte, North
Carolina
2014 Fellow, American Association for the Study of Liver Diseases
2016 Visiting Lecturer, Medical College of Wisconsin, Milwaukee, Wisconsin
2016 Outstanding Contribution Award. Journal of Clinical and Translational
Hepatology
Saab 6
2017 Outstanding Contribution Award. Journal of Clinical and Translational
Hepatology
2019 Visiting Lecturer, UCSF – Fresno Medical Center, Fresno, California
JOURNAL REFERREE ACTIVITIES
Associate Editor Digestive Medicine Research (DMR)
Journal of Clinical and Translational Hepatology
Journal of Clinical Gastroenterology
Assistant Editor American Journal of Gastroenterology
Liver International
World Journal of Gastroenterology
Reviewer
American Journal of Gastroenterology
American Journal of Medicine
Clinical Transplantation
Gastroenterology
Gastroenterology & Hepatology
Hepatology
Liver Transplantation
RESEARCH MENTORING
Name Year
High School
Teddy Alpers 2013
Ernesto Sernas 2014
Caterina Kachadoorian 2014
Naadir Jamal 2014 - 2015
Zoha Jamal 2015
Tori Alper 2015, 2017
Alexander Farid 2015 - 2016
Elena Saab 2015 - 2017
Alex Lee 2017
College Students
Pari Pruthi 2013 - 2014
Crystal Wu 2013 - 2016
Tiffany Wong 2013 - 2016
Melissa Jimenez 2014 - 2015
Theodore Alper 2014 - 2015
Matthew Viramontes 2015 - 2017
Caterina Kachadoorian 2016 - 2017
Saab 7
UCLA Medical Students
Amanda Chi 2007 - 2008
Calvin Nguyen 2008 - 2009
Benjamin Waterman 2009 - 2010
Kelvin Nguyen 2010 - 2011
Michael Choi 2011 - 2012
Jessica Ferguson 2012 - 2014
Edwin Lee 2014
Edward Chang 2014
Peter Konyn 2016
Philip Chen 2017
Emily Truong 2017
Dana Song 2018
UCLA Medical Residents
Robert Lin 2000 - 2002
Albert Chang 2002 - 2003
Denise Kalmaz 2003 - 2004
Shannon Lewis 2003 - 2004
Dan Cho 2003 - 2005
Stephen Nguyen 2005 - 2006
Christine Wiese 2006 - 2007
Mamie Dong 2006 - 2008
Maggie Ham 2008 - 2009
Vickie Wu 2008 - 2009
Bijal Surti 2008 - 2009
Melina Yeganh 2008 - 2009
Hiliary Bownik 2008 - 2010
Vivian Ng 2008 - 2011
Michael McTigue 2009 - 2010
Shirena Desai 2009 - 2012
Michael Chang 2010 - 2012
Kareem Sassi 2011 - 2012
Kali Zhou 2012 - 2014
Adam Greenberg 2014 - 2015
Sara Park 2015 – 2015. Recipient of AASLD Emerging Liver Scholar
Resident Travel Award
Elizabeth (Lizzie) Aby 2015 – 2015. Recipient of AASLD Emerging Liver Scholar
Resident Travel Award
Harman Rahal 2018 - present
Nathan Kim 2019 - present
Eric Wu 2019 - present
Saab 8
UCLA Gastroenterology Fellows
Shibhan Weston 2002 - 2003
Jose Nieto 2004 - 2006
Andrew Kim 2006 - 2007
Lenna Martyak 2007 - 2008
Carmen Landaverde 2007 - 2009
Jennifer Tan 2007 - 2009
Justin Reynolds 2012 - 2013
Vivian Ng 2012 - 2013
Gina Choi 2013 - 2014
Victoria Sheen 2014
Tyrlaee Goo 2014 - 2015
Kelvin Nguyen 2016 - 2018
Ani Kardashian 2017-2018
Adam Winters 2019-2020
Medical Residents at outside Institutions
Vincent De Rosa 2002 - 2003 West VA Medical Center
Jose Nieto 2002 - 2004 West VA Medical Center
Victor Wang 2003 - 2004 West VA Medical Center
Andrew Kim 2004 - 2005 West VA Medical Center
Alex Shpaner 2004 - 2006 West VA Medical Center
Carmen Landaverde 2005 - 2006 Olive-View Medical Center
Mina Oh 2006 - 2007 Cedars-Sinai Medical Center
J Carlos Hernandez 2007 - 2008 Harbor-UCLA Medicine Resident
Douglas Hunt 2007 - 2009 Harbor-UCLA Medicine Resident
Divya Mallam 2013 Harbor - UCLA Medicine Resident
Eshan Akhtar 2014 Harbor - UCLA Medicine Resident
Justin Rheem 2014 - 2017 Harbor - UCLA Medicine Resident
Duminda Suraweera 2014 - 2017 Olive-View Medical Center
Long Le 2017 - 2019 Olive-View Medical Center
UCLA Medical Student Courses
First year students
Liver Detoxification of Alcohol and Ammonia
Second year students
Jaundice and Cholestasis
Spectrum of Fatty Liver Disorders
Drugs and the Liver
Medical–Surgical GI Conference
Saab 9
RESEARCH FUNDING
Current
Principle Investigator: IDN-
6556-17: A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with
Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
(Conatus Pharmaceuticals)
Principal Investigator, A Multicenter, Randomized, Double-blind,
Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase
Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis
(Conatus Pharmaceuticals)
Co-Investigator, A Phase II Randomized Multicenter Placebo-Controlled
Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic
Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
(Bayer Pharmaceuticals)
Previous
Principal Investigator, A Multicenter, Double-Blind, Randomized Trial of
IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and
Liver Fibrosis or Cirrhosis Following Orthotopic Liver Transplantation for
Chronic HCV Infection and Who Subsequently Achieved a Sustained
Virologic Response Following anti-HCV Therapy (Conatus
Pharmaceuticals)
Principal Investigator, A randomized, open-label, multicenter, efficacy
and safety study of PEGASYS® for the treatment of hepatitis C virus
infection administered to patients six to sixty months post liver
transplantation (Roche Pharmaceuticals)
Co-Investigator, Fungal Prophylaxis with Liposomal Amphotericin B or
Amphotericin B Lipid Complex in patients undergoing liver
transplantation (Fujisawa Healthcare/Astellas)
Co-Investigator, Adult to Adult Living Liver Transplantation (U01-
National Institute of Health)
Investigator, A Double-Blind, Randomized, Placebo-Controlled Multi-
Center, Phase II Parallel Dose-Ranging study to Assess the Antifibrotic
Activity of GI262570 in Chronic Hepatitis C Subjects with Hepatic
Fibrosis who Have Failed Prior Antiviral Therapy (FBX 104114) (Glaxo).
Co-Investigator, A prospective, open-label, multi-center, randomized trial
of the efficacy and safety of a long-term calcineurin inhibitor free
maintenance regimen with Mycophenolate Mofetil and sirolimus in
Saab 10
recipients of an orthotopic liver transplant. Protocol Number: ML18423
(Roche Pharmaceuticals)
Principal Investigator, A Phase 3, Safety and Efficacy Study of Boceprevir
in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1
(Schering Plough)
Co-Investigator, Models for Liver Transplantation Outcomes (R01-
National Institute of Health
Principal Investigator, Phase 3 Safety and Efficacy Study of
Erythropoietin Use During Treatment of Subjects with Chronic Hepatitis
C with Boceprevir Peginterferon Alfa 2B, and Ribavirin (Schering
Plough)
Investigator, Interferon-induced Graft Function after Liver
Transplantation: Multicenter Case-Control Study (Northwestern
University/Schering Corporation)
Principal Investigator
A Multi-Center, Randomized, Open Label, Controlled Study to Compare
the Sustained Virological Response During Treatment with Neoral or
Tacrolimus in Maintenance Liver Transplant Recipients Treated with
Pegylated Interferon and Ribavirin for Recurrent Hepatitis C (Novartis
Pharmaceuticals)
Investigator
PROTECT-Pegylated Interferon alfa-2b and Ribavirin After Orthotopic
Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence
Therapy (P04590) (Schering-Plough)
Co-Investigator
A randomized, open-label, multicenter, efficacy and safety study of
PEGASYS® and Copegus as a against hepatitis C virus infection
recurrence after liver transplantation (Roche Pharmaceuticals)
Co-Investigator
A prospective, randomized, open label 26 week study of the efficacy and
safety of converting post-kidney and liver transplant patients with
tacrolimus-associated abnormal glucose metabolism to Neoral with C-2h
monitoring. (Novartis Pharmaceuticals)
Principal Investigator
A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging
Parallel Group Study to Compare the Anti-Viral Effects,
Pharmacokinetics, and Safety of HepeX-B as Compared to Hepatitis B
Immune Globulin in Patients Who Have Received Hepatic Allografts
for Hepatitis Virus Infection. (XTL Biopharmaceuticals, Inc)
Saab 11
Co-Investigator
Comparison of PEG Interferon alfa-2b plus Ribavirin Given as a Fixed
dose or on a weight optimized basis for treatment of chronic hepatitis C in
previously untreated adult subjects (Schering Pharmaceuticals)
Co-Investigator
A randomized, open-label, multicenter, efficacy and safety study of
PEGASYS® as a prophylaxis against hepatitis C virus infection
recurrence after liver transplantation (Roche Pharmaceuticals)
Principal Investigator
Epidemiology of hepatitis C in the hemodialysis community. Designed
decision analysis models for hepatitis C screening in hemodialysis patients
(AASLD/Schering Fellowship Award)
Post-Doctoral Fellow
Study of receptor mediators of hepatic stellate cell contraction (National
Institute of Health Training Grant)
LECTURES AND PRESENTATIONS
National
1991 Seminar ~ Misidentification, Biology and Culture
University of California at Los Angeles, Neuropsychiatric Institute
Los Angeles, California
1996 Department of Medicine Grand Rounds ~ AIDS and Ascites
University of California at San Diego, Medical Center
San Diego, California
1998 VA/UCLA CURE Annual Clinical Research Meeting ~ Risk Factors for
the Development of Hepatocellular Carcinoma
West Los Angeles VA Medical Center, Los Angeles, California
1999 Division of Gastroenterology Grand Rounds ~ Hepatitis A Cost-Preferred
Vaccine Strategies
West Los Angeles VA Medical Center, Los Angeles, California
1999 Current Topics in Gastroenterology ~ Vaccination Strategies for
Hepatitis A Infection
Nassau, Bahamas
1999 VA/UCLA CURE Annual Research Meeting ~ The Role of
Aminotransferases to Screen for Viral Hepatitis in Hemodialysis Patients
West Los Angeles VA Medical Center, Los Angeles, California
2000 Southern California Society of Gastroenterology ~Update on Hepatitis C
Treatment
Santa Barbara, California
2001 AIDS Project Advocacy Annual Seminar ~ Update on Hepatitis C
AIDS Project Advocacy, Los Angeles, California
2001 Pathophysiology of Diseases ~ Cirrhosis
Saab 12
Second year medical student lecture, UCLA School of Medicine
2002 Department of Pharmacy Grand Rounds ~ Update on Hepatitis C:
Epidemiology, Natural History, and Treatment
West Los Angeles VA Medical Center, Los Angeles, California
2002 Pathophysiology of Diseases ~ Cirrhosis
Second year medical student lecture, UCLA School of Medicine
2002 Department of Medicine Grand Rounds ~ Update on Hepatitis C
University of California Los Angeles, Medical Center
Los Angeles, California
2002 Department of Medicine Grand Rounds ~ Hepatitis C Diagnosis and
Management
Good Samaritan Hospital, Los Angeles, California
2002 Department of Pathology Grand Rounds ~ Natural History, Epidemiology,
and Diagnosis of Hepatitis C
University of California Los Angeles, Medical Center
Los Angeles, California
2003 Update on Hepatitis C ~ Natural History and Diagnosis
Southern California Society of Gastroenterology
2003 Hepatitis B ~ Evaluation and Management
Arthur Ashe Student Health and Wellness Center
Los Angeles, California
2003 Department of Medicine Grand Rounds ~ Liver Transplantation in the era
of MELD
University of California Los Angeles, Medical Center
Los Angeles, California
2003 Hepatitis C ~ Current Status
Arthur Ashe Student Health and Wellness Center
Los Angeles, California
2003 Division of Nephrology Grand Rounds ~ The Impact of Hepatitis C on
Patients with Kidney Disease
West Los Angeles VA Medical Center, Los Angeles, California
2004 Hepatitis C ~ Evaluation and Management
Hemophilia Center
Orthopedics Hospital, Los Angeles, Californi
2004
2004 Update on Hepatitis C and Liver Transplantation
Southern California Society of Gastroenterology
2004 Liver Cirrhosis: Current Management
Kaiser Permanente, Panorama City
2004 UCLA Update in Gastroenterology and Hepatology ~ Chronic Hepatitis
with Negative Viral Serologies
Century City, California
2004 Department of Pathology and Laboratory Medicine ~ Chronic Viral
Hepatitis
University of California Los Angeles, Medical Center
Los Angeles, California
2004 Division of Nephrology Grand Rounds ~ Current Concepts of Hepatitis C
in Patients with Kidney Disease
Saab 13
West Los Angeles VA Medical Center, Los Angeles, California
2004 Hepatitis C – Update in treatment and diagnosis
Chronic Liver Diseases and Hepatocellular Carcinoma: State-of-the-Art
Management. David Geffen School of Medicine at UCLA
2004 Department of Medicine Grand Rounds ~ Expanding Hepatitis C Care:
Managing Side Effects and Comorbidities.
VA Pacific Islands Health Care System, Honolulu, Hawaii
2004 State-of-the-Art Controversies: Steroid withdrawal vs No steroid
withdrawal for Hepatitis C.
Third International Congress on Immunosuppression
San Diego, California
2005 UCLA Update in Gastroenterology and Hepatology ~ Understanding and
Treating Non-viral Causes of Chronic Hepatitis
Beverly Hills, California
2005 Department of Medicine Grand Rounds ~ Treating Hepatitis C and HIV
Coinfection
Cottage Hospital, Santa Barbara, California
2005 American Transplant Congress Annual Scientific Meeting – Sunrise
Symposia on Improving Patient Outcomes Screening ~ Patients with
Cirrhosis (Chair and Speaker)
Seattle, Washington
2005 Kaiser Permanente National Gastroenterology Conference ~ Chronic
Hepatitis B: Evolving Treatment Strategies
Las Vegas, Nevada
2005 Emerging Treatments for Liver and Complex ~ Hepatitis B virus:
Treatment all Patients Now vs Delay Treatment
San Francisco, California
2005 Treatment of HIV/HCV Coinfection ~ Kaiser Permanente
Hollywood, California
2005 Treating Hepatitis - Maximizing Response and Minimizing injury (CME
activity) Los Angeles, California
2005 Treatment of HIV/HCV Coinfection ~ A Hepatologist Perspective (CME
activity) Santa Monica, California
2005 Southern California Society of Gastroenterology ~ Update on Hepatitis C
Laguna Beach, California
2005 Department of Medicine Grand Rounds ~- Current and Upcoming
Treatments (CME activity) and Treatment of Hepatitis B and C (CME
activity) ~ Doctor’s Hospital Medical Center, Montclair, California
2006 UCLA Gastroenterology Symposium ~ Screening for HCC and Biliary
Cancer in High-Risk Patients: What Should we be Doing? (CME activity)
~ Beverly Hills, California
2006 Hepatitis B and Infectious Disease Training Program ~ Review of Viral
Hepatitis, Discovery of HBV and Natural History (CME activity) ~
Beverly Hills, California
2006 Hepatitis B and Infectious Disease Training Program ~ Treatment
Guidelines (CME activity) ~ Beverly Hills, California
Saab 14
2006 UCLA State-of-the-Art Treatment for Diseases of the Liver ~ Improved
Efficacy of Hepatitis C Treatment, with Current and Future Therapies
(CME activity) ~ Costa Mesa, California
2006 UCLA Case Manager Update 2006 ~ Update on Hepatitis C (CME
activity) ~ Los Angeles, California
2006 Digestive Disease Week Combined Clinical Symposium ~ Care of the
Liver Transplant Patient in a Non-Transplant Center ~ Recurrent Disease
in Liver Transplant Recipients (CME activity) ~ Los Angeles, California
2007 Department of Medicine Grand Rounds ~ Chronic Hepatitis C Infection ~
Charles Drew University, Martin Luther King, Jr Hospital, Los Angeles,
California
2007 Department of Medicine UCLA Board Review Course ~ Viral Hepatitis
and other Liver Diseases ~ Center for Health Services, Los Angeles,
California
2007 Hepatitis C and Infectious Disease Training Program ~ Treatment
Guidelines (CME activity) ~ Los Angeles, California
2007 Common Causes of Hepatitis: Evaluation and Management (CME
activity) ~ Antelope Valley Hospital ~ Lancaster, California
2007 Department of Medicine Grand Rounds ~ Update in Chronic Hepatitis C
Infection: Current and Future Infections ~ Harbor-UCLA Medical Center,
Torrance, Los Angeles, California
2007 Hepatitis B in the Asian-American Community (CME activity)
University of the East Ramon Magsaysay Medical Alumni Association,
Buena Park, California
2007 Optimal Treatment in Hepatitis C (CME activity)
www.hcvcme.tv
2007 Hepatitis B and Infectious Disease Training Program ~ Review of Viral
Hepatitis, Discovery of Hepatitis B and Natural History (CME activity) ~
San Gabriel, California
2007 Division of Nephrology Grand Rounds ~ Hepatitis C in Renal Failure:
Impact and Treatment ~ Harbor-UCLA Medical Center, Torrance, Los
Angeles, California
2007 Division of Liver Transplantation Grand Rounds ~ To Treat or Not to
Treat Hepatitis C Cirrhosis ~ University of California Los Angeles,
Medical Center Los Angeles, California
2007 Department of Medicine Grand Rounds ~ Hepatitis B – Update in
Diagnosis and Treatment Guidelines (CME activity)~ Tuscon Medical
Center, Tuscon, Arizona
2007 Department of Medicine Grand Rounds ~ Hepatitis C – Current Strategies
in Diagnosis and Treatments (CME activity)~ Billings Medical Center,
Billings, Montana
2007 Department of Medicine Grand Rounds ~ Management and Treatment of
Chronic Hepatitis C. (CME activity)~ Huntington Memorial Hospital,
Pasadena, Montana
2007 Hepatitis C and Infectious Disease Training Program ~ Review of Viral
Hepatitis, Discovery of Hepatitis C and Natural History (CME activity) ~
San Gabriel, California
2007 Advances in Transplantation ~Changing the Natural History of
Saab 15
Hepatitis C in Liver Transplant Recipients (CME activity)~ San Diego,
California
2007 Advances in Transplantation ~Strategies in Hepatitis B Therapy in Liver
Transplantation (CME activity)~ San Diego, California
2007 Department of Medicine Grand Rounds ~ Fatty Liver –Diagnosis and
Treatment (CME activity)~ Providence Medical Center, Mission Hills,
California
2007 Third Annual University of California Irvine Hepatology Symposium
2007 ~ Treatment of Hepatitis C Infections in Special Populations (CME
activity) ~ Palm Springs, California
2007 General Hepatology Update ~ American Association for the Study of
Liver Diseases ~ Moderator ~ Boston, Massachusetts
2007 Hepatitis B: Diagnosis and Management ~ Asche Arthur Student Health
and Wellness Center ,UCLA, Los Angeles, California
2007 Hepatocellular Carcinoma: Multi-Disciplinary Management 2007 (CME
activity) ~ Chemotherapy and Chemo Prevention of HCC ~ Session Chair
~ Los Angeles, California
2008 Strategies in Hepatitis B Management – Pre and Post Liver
Transplantation ~ Liver Institute, Methodist Dallas Medical Center ~
Dallas, Texas
2008 Department of Medicine Grand Rounds ~ Management of Hepatitis B
(CME activity)~ St Joseph Hospital, Orange, California
2008 Department of Medicine Grand Rounds ~ Current Strategies in the
Diagnosis and Treatment of Chronic Hepatitis B Infection (CME
activity)~ Providence Little Company of Mary Hospital, California
2008 Refractory Ascites Clinical Symposium for the American Association for
the Study of Liver Diseases ~ Clinical Impact of Refractory Ascites ~
Digestive Disease Week, San Diego, California
2008 Hepatitis B and Infectious Disease Training Program ~ Review of
Resistance and Treatment Guidelines (CME activity) ~ San Gabriel,
California
2008 Department of Medicine Grand Rounds ~ Current and Future Trends in
Hepatitis C Treatment (CME activity) ~ Harbor-UCLA Medical Center,
Torrance, Los Angeles, California
2008 Managing Adverse Effects with Hepatitis C Antiviral Therapy (CME
activity). www.hcvcme.tv
2008 Department of Surgery Grand Rounds ~ Immunosuppressant Strategies in
Liver Transplant Recipients ~ Los Angeles Kaiser Permanente, Los
Angeles, California
2008 Department of Anesthesiology Grand Rounds ~ Hepatitis C Viral
Infection: Diagnosis and Management Strategies (CME activity) ~
Harbor-UCLA Medical Center, Torrance, Los Angeles, California
2008 Thomas Street Health Center ~ Managing Treatments for Hepatitis C
Nonresponders and Relapsers (CME activity) ~ Houston, Texas
2008 Department of Medicine Grand Rounds ~ Management of Cirrhosis, and
its Complications (CME activity) ~ Providence Little Company of Mary
Hospital, California
Saab 16
2008 Division of Gastroenterology Grand Rounds ~ Treatment of Hepatitis C:
Before and After Transplantation ~ University of Pennsylvania,
Philadelphia, Pennsylvania
2008 Second Annual UCLA Liver Diseases Symposium ~ Management of
Cirrhosis, and its Complications (CME activity) ~ University of California
Los Angeles, Pasadena, California
2008 Southern California Society of Gastroenterology ~ Hepatitis C - Current
Treatments (CME activity). Laguna Beach, California
2009 Emerging Medical Therapies for Hepatitis C ~UCLA Liver
Transplantation Scientific Symposium, Los Angeles, California
2009 Controversies in Treating Hepatitis C before and after Liver
Transplantation ~ LifeLink HealthCare Institute, Tampa, Florida
2009 Pacific Hospital of Long Beach ~ Chronic Viral Hepatitis
Long Beach, California
2009 Health Effects of Alcohol: What your Patients and Clients need to know ~
Viral Hepatitis, Alcohol and liver Transplantation (CE activity) Alhambra,
California
2009 Department of Medicine Grand Rounds ~ Complications of Cirrhosis and
Hepatocellular Carcinoma (CME activity) ~ John F Kennedy Memorial
Hospital, Indio, California
2009 American Transplant Congress Annual Meeting ~ Quality of Life in Liver
Transplant Recipients ~ Boston, Massachusetts
2009 Department of Medicine ~ Management Strategies for the Hepatitis C
Treatment Failures ~ Winthrop University Hospital, New York, New York
2009 Outpatient Management of GI/Hepatology Diseases ~Update on Post-
Liver Transplant Immunosuppressive Management ~ University of
California Irvine Healthcare ~ Orange, California
2009 Department of Medicine Grand Rounds ~ New Treatment Options and
Strategies for Hepatitis C (CME activity) ~ Parkview Community Medical
Center, Riverside, California
2009 Hepatitis C ~ Training Program and Treatment Update (CME activity) ~
San Gabriel, California
2009 Assessing Recent Advancements in the Management of ITP and
Thrombocytopenia Secondary to Other Disorders ~ Managing
Thrombocytopenia in Patients with Chronic Liver Disease (CME activity)
~ Los Angeles, California
2009 Department of Medicine Grand Rounds ~ Diagnosis, Clinical Implications
and Treatment of Hepatitis C (CME activity) ~ University of California
Los Angeles ~ Los Angeles, California
2009 Prevention and Management of Esophageal Variceal Hemorrhage. ~
Meet-the Professor Luncheon ~ American Association for the Study of
Liver Diseases ~ Boston, Massachusetts
2009 Third Annual UCLA Liver Diseases Symposium ~ Current and Future
Treatment of Hepatitis C~ (CME activity) ~ University of California Los
Angeles, Pasadena, California
2009 53rd Annual Raymond M. Kay, MD Internal Medicine Symposium ~
Evaluation of Liver Enzymes (CME activity) ~ Kaiser Permanente,
Rancho Mirage, California
Saab 17
2009 Treatment of Unresectable Hepatocellular Carcinoma ~New Mexico
Cancer Center~ Albuquerque, New Mexico
2009 Evaluation of Patients with Unresectable Hepatocellular Carcinoma ~
University of Texas Memorial Herman ~ Houston, Texas
2009 Strategies in Patients with Hepatocellular Carcinoma~ Liver Institute at
Methodist Dallas Medical Center ~ Dallas, Texas
2009 Division of Gastrointestinal Grand Rounds ~ Hepatocellular Carcinoma:
Implications, Diagnosis and Management (CME activity) ~ University of
Texas Southwestern Medical Center ~ Dallas, Texas
2009 Southern California Society of Gastroenterology ~ AASLD 2009 Update
on Non-genotype 1 Patients (CME activity). Dana Point, California
2009 Inland GI Midlevel Network ~ Update on AASLD 2009 ~ Riverside,
California
2009 Medical Grand Rounds ~ New Strategies in Hepatitis C Therapy ~ Hemet
Valley Medical Center ~ Hemet, California
2010 Sierra Sacramento Valley Medical Society~ What the Liver can do for
You (CME activity ~ Sacramento, California
2010 Medical Grand Rounds ~ Management of Cirrhosis and Hepatocellular
Carcinoma (CME activity) ~ Valley Presbyterian Hospital, Van Nuys,
California
2010 Medical Grand Rounds Grand Rounds ~ Fatty Liver ~ A Sleeping Giant
(CME activity) ~ Overlake Hospital Medical Center, Bellevue,
Washington
2010 Medical Grand Rounds ~Hepatic Lesions ~ Incidental and Non-Incidental
Lesions (CME activity) ~ Providence Holy Cross Medical Center, Mission
Hills, California
2010 Arapahoe Gastroenterology Pow-Wow Conference ~ Approach to the
Patient with Hepatitis B. Littleton, Colorado
2010 Evaluation in Chronic Hepatitis C (CME activity) ~ Henderson County
Medical Society, Athens, Texas
2010 Management of Side Effects of Therapy ~Complications of Hepatitis C
(CME activity) ~Audio-Digest Gastroenterology.
2010 Hepatitis B Diagnosis and Treatment (CME activity) ~ California
Association Nurse Practitioners ~ West LA Chapter, Beverly Hills,
California
2010 Hepatitis C ~ Training Program and Treatment Update (CME activity) ~
San Gabriel, California
2010 11th Annual International Hot Topics in Liver Disease Conference
~Treating Hepatocellular Carcinoma (CME activity)~Houston, Texas
2010 Pri-Med ~Chronic Hepatitis B Virus Infection: Screening and Linkage to
Care in the Asian Community (CME activity) ~ Chicago, Illinois
2010 Hepatitis C in Special Populations (CME activity) ~ Asian Physician
Group ~ Fountain Valley, California
2010 Hepatitis B ~ AASLD 2010 Update (CME activity) ~ Texas Gulf Coast
Gastroenterological Society ~ Houston, Texas
2010 Hepatitis C: Clinical Impact, Natural History, and Treatment ~ Hepatitis C
Task Force for Los Angeles ~ Los Angeles, California
Saab 18
2010 Fourth Annual UCLA Liver Diseases Symposium ~ Current and Future
Treatment of Hepatitis C~ (CME activity)~ University of California Los
Angeles, Pasadena, California
2010 Southern California Society of Gastroenterology ~ Hepatitis B Resistance
and Safety Concerns -(CME activity). Dana Point, California
2010 Hepatitis Symposium ~ Hepatocellular Carcinioma ~ Screening,
Diagnosis, and Management. -(CME activity). Honolulu, Hawai‘i
2010 Chronic Hepatitis C Virus Infection: Screening and Linkage to Care -
(CME activity). Hilo Medical Center Grand Rounds, Hilo, Hawai‘i.
2011 Association of Black Woman Physicians. Best Practices for the
Management of Hepatitis C: Screening, Linkage to Care, and Treatment -
(CME activity) ~ West Hollywood, California
2011 Medical Grand Rounds ~ Hepatitis C: Diagnosis and Management (CME
activity) ~ Harbor-UCLA, Torrance, California
2011 Post-Conference Update 2010: ACG and AASLD. Association of Black
Women Physicians, Rancho Palos Verdes, California
2011 Hepatitis B: From Diagnosis to Treatment. Kern Medical Center,
Bakersfield, California
2011 Hepatitis C: From Diagnosis to Management (CME activity) ~ Asian
Physician Medical Group ~ Rosemead, California
2011 Hepatocellular Carcinoma: Risk Factors, Screening, Surveillance, and
Staging (CME activity). Improving Medical Practice by Advancing
Clinical Therapeutics, Los Angeles, California
2011 Medical Grand Rounds ~Viral Hepatitis: Epidemiology, Diagnosis,
Treatment (CME activity) ~ West Hills Medical Center, West Hills,
California
2011 Medical Grand Rounds ~ Hepatitis C: Diagnosis and Management.
Tillamook Country General Hospital, Tillamook, Oregon
2011 Medical Grand Rounds ~ Address Hepatitis C Clinical Gaps among
Special Patient Populations. (CME activity) ~ Veteran Affairs Los
Angeles Ambulatory Care Center, Los Angeles, California.
2011lamook National End Stage Liver Disease Training Program and Treatment
Update 2011 (CME activity) ~ Scripps Clinic, Pasadena, California
2011 Hepatitis B Management Considerations for Women of Child-Bearing
Age and Pregnancy (CME activity) ~ Asian Physician Medical Group ~
Rosemead, California
2011 Medical Grand Rounds ~ Impact of Chronic Liver Disease (CME
activity) ~ St. Joseph's Medical Center ~ Modesto, California
2011 Ninth Annual Offsite CME Meeting ~ Hepatitis B Management
Considerations for Women of Childbearing Age and Pregnancy (CME
activity). Armenian American Medical Society of California ~ Las Vegas,
Nevada
2011 Gastroenterology Conference 2011 ~ ABCs of Hepatitis (CME
activity) ~ Antelope Valley Hospital, Lancaster, California.
2011 Infectious Disease Grand Rounds ~ Emerging Therapy for Chronic
Hepatitis C (CME activity) ~ Los Angeles County and the University of
California Medical Center ~ Los Angeles, California
2011 Fifth Annual UCLA Liver Diseases Symposium ~ Current Treatment of
Saab 19
Hepatitis C~ (CME activity) ~ University of California Los Angeles,
Pasadena, California
2011 Plenary Session ~ 9th Annual Hepatitis Summit Viral Hepatitis Overview –
Hepatitis C Task Force for Los Angeles ~ Los Angeles, California
2012 Annual Spring CME Conference ~ Clinical Perspectives in the
Management of Chronic Hepatitis B Infection ~ (CME activity) ~
Armenian American Medical Society Glendale, California
2012 American College of Physicians Annual Meeting ~ Chronic Hepatitis:
The Bs and Cs (CME activity) ~ American College of Physicians ~ New
Orleans, Louisiana
2012 2012 Annual Federal Hemophilia Treatment Centers Conference for
Region IX “Challenges of Living Longer with Hemophilia” ~ Hepatitis C
– Update on the Latest Treatments ~ Santa Monica, California
2012 Hyponatremia – Clinical Implications and Managments. Santa Clara
Valley Medical Center, Santa Clara, California.
2012 Hepatitis C: Understanding and Combating a Hidden Disease(CEU
activity) ~ The California Partnership, Los Angeles, California
2012 National Hepatitis B and C Training Program and Treatment Update 2012
(CME activity) ~ Scripps Clinic, Los Angeles, California
2012 National End Stage Liver Disease Training Program and Treatment
Update 2012 (CME activity) ~ Scripps Clinic, Hollywood, California
2012 Update! Advances in Hepatitis C Current and Future Treatment – The
World is Changing! ~ National AIDS Treatment Advocacy Project, Los
Angeles
2012 Unmet Needs in Hepatitis C (CME activity)~ University of Santo Tomas
Medical Alumni Association in America Convention - Caesars Palace
Convention Center, Las Vegas, Nevada
2012 Hepatitis C. Update on Direct Acting Agent Therapy (CME Activity) ~
National Liver Conference 2012, San Antonio, Texas
2012 Medical Grand Rounds ~ Hepatitis A through C: Diagnosis, Natural
History and Management (CME activity) ~ Torrance Memorial Medical
Center, Torrance, California
2012 Sixth Annual UCLA Liver Diseases Symposium ~ Hepatitis C: Update
on Screening, Epidemiology, and Management~ (CME activity) ~
University of California Los Angeles, Pasadena, California
2012 Medical Grand Rounds ~ Fatty Liver Manifestation of the Metabolic
Syndrome: Diagnosis, Natural History and Treatment (CME activity) ~
West Hills Hospital, West Hills, California
2013 Medical Grand Rounds ~ Fatty Liver Manifestation – A Sleeping
Giant (CME activity) ~ Providence Holy Cross Medical Center, Mission
Hills, California
2013 Infectious Disease Grand Round ~ Management Considerations for
Hepatitis B Co-Infection with Hepatitis C or HIV. University of Southern
California Medical Center, Los Angeles, California
2013 Liver Transplant Grand Round ~ Fatty Liver and Liver Transplantation.
University of California Los Angeles, Los Angeles, California
Saab 20
2013 Medical Grand Rounds ~ Clinical Advances in the Management of
Cirrhosis and its Complications (CME Activity) ~ Eisenhower Medical
Center, Rancho Mirage, California.
2013 Viral Hepatitis Liver Transplantation: Pre and Post-Transplant
Management Clinical Symposium. Hepatitis B: HBIG Out, Antivirals In.
American Association for the Study of Liver Disease. Digestive Disease
Week, Orlando, Florida.
2013 Chronic Hepatitis B: New Trends and Treatment (CME Activity). 21st
USTMAAA Medical Convention. Waikiki, Hawaii.
2013 Chronic Hepatitis C: Diagnosis and Management (CME Activity). 21st
USTMAAA Medical Convention. Waikiki, Hawaii.
2013 National Hepatitis B and C Training Program and Treatment Update
2013 (CME activity) ~ Hepatitis C. Scripps Clinic, Los Angeles,
California
2013 American College Gastroenterology 2013 (CME Activity) ~ The
Incidental Liver Lesion,: How to Follow, When to Refer San Diego,
California
2013 Seventh Annual UCLA Liver Diseases Symposium ~ Hepatitis C: Present
and Future Therapy ~ (CME activity) ~ University of California Los
Angeles, Pasadena, California
2013 Chronic Hepatitis C Bridging Diagnosis and Management ~ (CME
activity) American Association of Critical Care Nurses. Costa Mesa,
California.
2013 Chronic Hepatitis C ~ Screening and Diagnosis ~ (CME activity)
Armenian American Nurses Association. Studio City, California
2014 GI Issues for the Primary Care Physician ~ Clinical Advances in the
Management of Cirrhosis and Its Complications ~ (CME activity) ~ Los
Angeles, California
2014 2nd Annual UCLA-Mellinkoff Gastroenterology Symposium
Therapeutics in Gastroenterology ~ Treatment of Hepatitis C (CME
activity) ~ Los Angeles, California
2014 Third Spring Conference Medical Update ~ Clinical Perspectives in the
Management of Chronic Hepatitis C Infection~ (CME activity) ~
Armenian American Medical Association. Glendale, California
2014 Medical – Surgical Grand Rounds ~ Fatty Liver – The Sleeping Giant
(CME Activity) St Vincent’s Medical Center, Los Angeles, California
2014 Medical Grand Rounds ~ Viral Hepatitis (CME Activity) Little
Company of Mary- San Pedro, California
2014 Phillipine Medical Society of Northern California ~ Complications of
Cirrhosis ~ Encephalopathy, Burlingame, California
2014 National Hepatitis B and C Training Program and Treatment Update
2014 (CME activity) ~ Hepatitis C. Scripps Clinic, Hollywood, California
2014 Surgical Grand Rounds ~ Update on Hepatology & Infectious
Diseases of the Liver for Surgeons. University of California Los Angeles
Medical Center.
2014 Annual Emerging Topics in Liver Disease Conference ~ Management
of Hepatitis C in the Era of Direct Acting Antiviral Therapy (CME
activity) ~ Houston, Texas
Saab 21
2014 The Seventeenth Conference on Health Care of the Chinese in North
America "Preventive Care: Opportunities and Challenges" ~
Hepatocellular Carcinoma, Millennium Biltmore Hotel, Los Angeles,
California
2014 Hepatitis C: New Developments in Treatment (CME activity) ~ Infectious
Disease Association of California, Irvine, California
2014 Eighth Annual UCLA Liver Diseases Symposium ~ Hepatitis C:
Current and Future Therapy ~ (CME activity) ~ University of California
Los Angeles, Los Angeles, California
2014 Hepatitis C Panel Discussant ~. Southern California Society of
Gastroenterology ~ Ritz-Carlton, Laguna Beach
2015 Medical Grand Rounds ~ Advances in Hepatitis C Management and
Treatment. Providence Tarzana Medical Center, Tarzana, Georgia
2015 Medical Grand Rounds ~ Fatty Liver. Northridge Medical Center,
Northridge, California
2015 Women's Health Case Conference ~ Fatty Liver Disease (CME activity) ~
University of California Los Angeles, Los Angeles, California
2015 Division of Nephrology Grand Rounds ~ New Advances in Hepatitis C ~
University of California Los Angeles, Los Angeles, California
2015 Spotlight on Hepatitis C Infection (CME activity) ~ Pri-Med Southwest
Annual Conference ~ Houston, Texas
2015 Third Annual UCLA-Mellinkoff Gastroenterology Symposium
Therapeutics in Gastroenterology ~ Viral Hepatitis. A New Dawn
(CME activity) ~ Los Angeles, California
2015 Pri-Med West Annual Conference ~Advances in Hepatitis C Infection
(CME activity) ~ Anaheim, California
2015 14th Annual GI Pow Wow! Chronic Hepatitis C - Update in Diagnosis and
Management (CME activity). ~ Denver, Colorado
2015 Pri-Med West Annual Conference ~Advances in Chronic Hepatitis C
Infection (CME activity) ~ Long Beach, California
2015 Department of Medicine Grand Rounds ~ New Advances in Hepatitis C
(CME activity) ~ Providence Holy Cross Medical Center, Mission Hills,
California
2015lamook National End Stage Liver Disease Training Program and Treatment
Update 2015 (CME activity) ~ Hepatitis C~ Scripps Clinic, Los Angeles,
California.
2015 Treating Hepatitis C related Cirrhosis. Texas Tech Health Science Center.
El Paso, Texas
2015 Third Annual End Stage Liver Disease Training Program and
Treatment Update 2015 (CME activity) ~ Scripps Clinic, La Jolla,
California
2015 Diablo Society of Health-System Pharmacists ~ Hepatic encephalopathy ~
Walnut Creek, California
2015 Hepatitis C – Cure has Arrive: Care and Treatment Management ~
National AIDS Treatment Advocacy Project ~ St Anne’s Conference, Los
Angeles, California
2015 Chronic Hepatitis C Treatment ~ Tule River Indian Reservation,
Porterville, California
Saab 22
2015 Current and Future Trends in Hepatitis C ~ 38th Annual Recognition
Program, Bakersfield Memorial Hospital, Bakersfield, California
2015 Medical Grand Rounds ~ Therapy in Difficult to Treat Patients with
Hepatitis C (CME activity) City of Hope, Duarte, California.
2015 Treating Patients with Advanced Liver Disease and Liver Transplant
Recipients for Hepatitis B (CME activity). California Northstate
University. Elk Grove, California.
2015 Medical Grand Rounds ~ Fatty Liver (CME activity) West Hills
Hospitals and Medical Center, West Hills, California
2015 Ninth Annual UCLA Liver Diseases Symposium ~ Current and Future
Hepatitis C Therapies (CME activity) ~ University of California Los
Angeles, Pasadena, California Pasadena, California
2015 Pri-Med West Annual Conference ~Advances in the Management of
Chronic Hepatitis C Infection (CME activity) ~ Los Angeles, California
2015 Medial Grand Rounds ~ Fatty Liver (CME Activity) ~ St. Joseph Medical
Center, Burbank, California.
2015 Medical Grand Rounds ~ Current Trends in Fatty Liver (CME activity) ~
Providence Holy Cross Medical Center, Mission Hills, California
2015 American Academy of Addiction Psychiatry ~ Advances in the
Management of Chronic Hepatitis C (CME) ~ Huntington Beach,
California
2015 Liver Summit 2015 ~ A Clinical Update on Primary Biliary Cirrhosis,
Non-alcoholic Fatty Liver Disease, Chronic Hepatitis B and C, Cirrhosis,
and Liver Cancer (CME) ~ Pasadena, California
2016 Advances in Hepatitis C Treatment ~ UCLA Motion Pictures Medical
Group, Woodland Hills, California.
2016 UCLA Clinical and Contemporary IR 2016 ~ New Treatments for
Hepatitis C (CME) ~ Santa Monica, California
2016 Fourth Annual UCLA-Mellinkoff Gastroenterology and Hepatology
Symposium. Current Practice and Future Trends in Gastroenterology ~
Hepatitis C ~ Vanishing Disease (CME activity) ~ Beverly Hills,
California
2016 Division of Infectious Diseases Medical Conference ~ Evolving
Management of Hepatitis C/HIV Coinfection (CME activity) ~ University
of California Irvine Medical Center, Orange, California
2016 Annual Internal Medicine Conference. Chronic Hepatitis C
Treatment Guidelines: Best Practices for Achieving a Cure (CME
activity) ~ Armenian American Medical Society of California.
Glendale, California
2016 Hepatitis C: A Primer for Primary Care (CME activity) ~ UCLA
Primary Care 2016 ~ Las Vegas, Nevada
2016 33rd Annual Spring Update. (CME activity) ~ Advances in Hepatitis C ~
Saint Francis Hospital, Memphis, Tennessee
2016 Clinical Symposium ~ Cost-Effectiveness of HCV Therapy by
Genotype. Maximizing the Value of Care for Patients with Chronic
HCV Infection. Digestive Disease Week. San Diego, California
2016 Medical Grand Rounds ~ Advanced in Liver Transplantation (CME
activity) ~ Northridge Hospital Medical Center, Northridge, California
Saab 23
2016 Nurse Course. Update on Hepatitis C. Laguna Niguel, California
2016 Post-Digestive Disease Week. Hepatitis Hot Topic: Hepatitis C (CME
activity). Southern California Society of Gastroenterology. Laguna
Niguel, California
2016 Rheumatology Grand Rounds ~ Autoimmune hepatitis ~ University of
California Los Angeles, Los Angeles, California
2016 40th American College of Osteopathic Family Physicians Annual
Scientific Medical Seminar. Chronic Hepatitis C ~ Screening, Diagnosing
and Referring. ACPFPCA, Anaheim, California.
2016 Tenth Annual UCLA Liver Diseases Symposium ~ Update on Chronic
Hepatitis C Management and Therapy (CME activity) ~ University of
California Los Angeles, Pasadena, California Pasadena, California
2016 Hepatic Encephalopathy: Economic and Social Burden, Hospital
Readmission and Cognition. Chronic Liver Disease Foundation, Chicago,
Illinois
2016 Medical/Surgical Grand Rounds ~ Liver Cirrhosis (CME/MOC activity) ~
St Vincent Medical Center, Los Angeles, California
2016 Medical Grand Rounds ~ Primary Biliary Cholangitis. Kern Medical
Center, Bakersfield, California
2016 Hepatitis C Case Discussion (CME activity) ~ Southern California
Society of Gastroenterology. Laguna Beach, California.
2017 Department of Medicine Grand Rounds ~ Current Management of
Hepatitis C ~ Working Toward Elimination (CME activity) ~ Harbor-
UCLA Medical Center, Torrance, Los Angeles, California
2017 Department of Medicine Grand Rounds ~ Advances in Chronic Hepatitis
C ~ Olive View - UCLA Medical Center, Sylmar, California
2017 Department of Medicine Grand Rounds ~ Hepatitis C Advances – (CME
activity) ~ Providence Holy Cross Medical Center, Mission Hills,
California
2017 Department of Family Medicine Grand Rounds ~ Current Concepts
in Cirrhosis– (CME activity) ~ UCLA- Santa Monica Medical Center,
Santa Monica, California
2017 Fifth Annual UCLA-Mellinkoff Gastroenterology and Hepatology
Symposium. Current Practice and Future Trends in Gastroenterology ~
Update on Hepatitis C (CME activity) ~ Beverly Hills, California
2017 Rocky Mountain Gastroenterology’s 16th Annual GI Pow-Wow
Conference ~ Diagnosis and Management of Autoimmune Liver Disease
B (CME activity). Denver, Colorado
2017 Hepatitis C: The Changing Climate in Transplant. (CEU activity).
University of California at Los Angeles, Los Angeles, California
2017 Medical Grand Rounds ~ Update on Primary Biliary Cholangitis (CME
activity). West Hills Hospital and Medical Center, West Hills, California
2017 Pri-Med ~Viral Hepatitis Infection Update (CME activity) ~ Irving, Texas
2017 11th Annual UCLA Liver Diseases Symposium ~ Best Options for
Treatment of Hepatitis C ~ (CME activity) ~ University of California Los
Angeles, Pasadena, California
2017 Medical Grand Rounds ~ Hepatitis C ~ The Final Countdown (CME
activity). Harbor-UCLA Medical Center, Torrance, California
Saab 24
2017 Annual Public Health Investigation Symposium ~ Hepatitis C: The New
Silent Epidemic. Rio Honda Country Club, Downey, California
2017 Hepatitis C Case Discussion – Management Strategies (CME activity) ~
Southern California Society of Gastroenterology. Laguna Beach,
California.
2017 2nd Annual Southern California Kidney Symposium: The Kidney
Crossroads of Whole Body Health and Disease ~ Management of
Hepatitis C and Kidney Disease (CME activity). University of Southern
California, Los Angeles, California
2018 Medical Grand Rounds ~ Elimination of Hepatitis C (CME activity) ~
University of California Los Angeles, California.
2018 Nephrology Grand Rounds ~ Association of Hepatitis C and Renal
Disease. University of California Los Angeles, California
2018 Sixth Annual UCLA-Mellinkoff Gastroenterology Symposium
Therapeutics in Gastroenterology ~ Hepatitis C: The Final Chapter
(CME activity) ~ Los Angeles, California
2018 Rocky Mountain Gastroenterology’s 17th Annual GI Pow-Wow
Conference ~ Update on Hemochromatosis (CME activity). Denver,
Colorado
2018 15th Annual Hepatitis C Summit. Hepatitis C: The Fight Continues.
California Endowment, Los Angeles, California
2018 Medical Grand Rounds: Fatty Liver ~ Current Management (CME
activity). Orange Coast Medical Center. Fountain Valley, California
2018 Triple E for Hepatitis C. Engagement, Education and Eradication of HCV
among Patients with Substance Use Disorders. 2018 National Conference
on Alcohol & Addiction Disorder (CME activity). Anaheim, California
2018 Department of Surgery Grand Rounds ~ Elimination of Hepatitis C.
University of California, Los Angeles, Los Angeles, California
2018 2018 Scripps Clinic National Hepatitis B&C Training Program and
Treatment Update. San Gabriel, California.
2018 Emerging Topics in Liver Disease Conference ~ State of the Art Lecture.
Nonalcoholic Fatty Liver Disease: Pathogenesis and Implications for
Medical Management (CME activity) ~ Sherrie and Alan Conover Center
for Liver Disease and Transplantation. Houston Methodist Hospital,
Houston, Texas
2018 Medical Grand Rounds. Fatty Liver. Pathogenesis, Diagnosis and
Treatment (CME activity) ~ Providence Holy Cross Medical Center,
Mission Hills, California A
2018 Rheumatology Grand Rounds. Spectrum of Autoimmune Liver Diseases.
Division of Rheumatology, University of California Los Angeles, Los
Angeles, California.
2018 Medical Update for the Psychiatrist. Hepatic Disease (CME activity).
MasterPsych, Santa Barbara, California
2018 Panel Discussion on Cholestatic Liver Diseases (CME activity). Southern
California Society of Gastroenterology. Laguna Beach, California
2019 PrimMed Annual Meeting. Hepatitis C: From Diagnosis to Cure (CME
activity). Fort Lauderdale, Florida.
2019 Seventh Annual UCLA-Melinkoff Gastroenterology Symposium
Saab 25
Therapeutics in Gastroenterology ~ Eliminating Hepatitis C: From
Diagnosis to Cure. (CME activity) ~ Beverly Hills, California
2019 Department of Medicine Grand Rounds ~ Fatty liver. From Diagnosis and
Management (CME activity). Good Samaritan Hospital, Los Angeles,
California
2019 Regional Summit Series on Gastrointestinal Malignancies (non-CME) ~
Hepatocellular Carcinoma. Pasadena California
2019 Department of Medicine Grand Rounds ~ Fatty Liver ~ Emerging Giant in
Healthcare (CME activity). UCSF Fresno Center. Fresno, California
2019 Department of Medicine Noon Lecture ~ Management of Cirrhosis:
Tailored Care (non-CME activity). UCSF Fresno Center. Fresno,
California
2019 Medicine Grand Rounds ~ Non-Alcoholic Fatty Liver Disease (CME
activity). Providence Holy Cross Medical Center. Mission Hills,
California.
2019 16th Annual Hepatitis C Summit. Identifying and Managing Patients with
Hepatitis C (non-CME activity). Los Angeles, California.
2019 National AIDS Treatment Advocacy Project (non-CME activity) ~ New
Approaches in Treating and Curing Hepatitis C. St Anne’s Conference,
Los Angeles, California
2019 Family Medicine Grand Rounds. Evolution in the management of
Hepatitis C - Changing Epidemiology and Treatment Indications (CME
activity). Santa Monica –UCLA Hospital, Santa Monica, California
2019 Review of Viral Hepatitis, Discovery of HCV and Natural History.
Hepatitis C. (CME activity). Scripps National Hepatitis B&C Training
Program and Treatment Update. Marina del Ray, California.
2019 Diagnostic Testing, Screening, Histology, Cirrhosis and Liver Biopsy.
Hepatitis C. (CME activity). Scripps National Hepatitis B&C Training
Program and Treatment Update. Marina del Ray, California.
2019 Antiviral Therapies for Hepatitis C. Hepatitis C. (CME activity). Scripps
National Hepatitis B&C Training Program and Treatment Update. Marina
del Ray, California.
2019 Updated Data from EASL 2019. Hepatitis C. (CME activity). Scripps
National Hepatitis B&C Training Program and Treatment Update. Marina
del Ray, California.
2019 Thirteenth Annual UCLA Liver Diseases Symposium ~ Hepatitis C:
Current Antiviral Treatments, Risk for Hepatocellular Carcinoma? (CME
activity) ~ University of California Los Angeles, Pasadena, California
2019 Medical Grand Rounds. Non-Alcoholic Fatty Liver Disease (CME
activity) ~Northridge Hospital Medical Center, Northridge, California
2019 Liver Symposium Panel Discussant (CME activity). Southern California
Society of Gastroenterology. Laguna Beach, California.
2020 Liver Transplantation for Alcohol Hepatitis (non-CME activity). Orange
County Gastroenterology Society. Santa Ana, California
2020 2020 Emerging Therapies for PBC, NASH, ESLD and HCC Seminar
Series (CME activity). Scripps Liver Research Consortium. Pasadena,
California.
Saab 26
2020 Eighth Annual UCLA-Melinkoff Gastroenterology Symposium
Therapeutics in Gastroenterology ~ Hepatitis C: The Gift That Keeps on
Giving (CME activity) ~ Beverly Hills, California
2020 Covid-19 and the Liver. Hot Topics in Cirrhosis: A Case-Based Approach
to Hepatorenal Syndrome and Acute Kidney Injury in Liver Disease.
(CME activity) ~ Los Angeles, California
2020 First Steps in HCV Elimination: Improved Screening and Linkage-to-Care
Approaches (CME activity). Orange County Gastroenterology Society.
Los Angeles, California
Saab 27
International
2006 Hepatitis C Symposium ~ What about the Relapser/Non-responder? Treat
or Maintain? ~ Sydney, Australia
2006 Hepatitis C Symposium ~ What’s in Store in the Future? ~ Sydney,
Australia
2007 Current Practices and Challenges of Hepatitis C Treatment for Special
Groups in the USA: Hepatitis C Disease Progression, Liver Transplant,
and End-Stage Renal Disease ~Bhusan, Korea
2008 International Hepatology – 2007 AASLD Highlight ~ Congress Chinese
Medical Association ~ Shanghai, China
2008 Extended Donors in Liver Transplantation ~ American Transplant
Congress ~ Toronto, Canada
2008 Managing Complications of Anti-Hepatitis C Therapy ~ American
Transplant Congress ~ Toronto, Canada
2008 Pregnancy and Liver Transplantation ~Joint International Congress of
ILTS, ELITA, and LICAGE ~ Paris, France
2009 State of Liver Transplantation: Current Problems, Future Solutions ~
Hepatitis C Treatments: On the Horizon ~ International Liver
Transplantation Society New York, New York
2009 ILTS Postgraduate Course: Quality of Life for Adult Recipients ~
International Liver Transplantation Society, Boston, Massachusetts
2011 Curbside Consultation and Case Discussion: Complications of Cirrhosis
(Meet the Professor Luncheon). Digestive Disease Week. Chicago,
Illinois
2011 2011 EASL Special Conference on Liver Transplantation. Cardiovascular
Complications: Minimizing Risks. ~ Lisbon, Portugal
2012 Scientific Committee of the Saudi Association of Liver Diseases and
Transplantation. Hepatitis C Treatment in the Transplant Setting.
Dammam, Saudi Arabia
2013 Saudi International Congress on New Frontiers in Organ Transplantation
2013. Advances in Hepatitis C Management Post Liver Transplantation.
Riyadh, Saudi Arabia
2013 Hepatitis B Screening (CME Activity). Internal Medicine
Multidisciplinary Session. 11th Armenian Medical World Congress. Los
Angeles, California
2014 Congreso de Medicina y Especialidades Kennedy Simposi de Hepatologia.
Update on Chronic Hepatitis B and C Treatment; Treatment of NASH;
Treatment of Hepatocellular Carcinoma; Indications and Contraindications
for Liver Transplantation. Guayaquil, Ecuador.
2015 New Direct Acting Agents: Can we Afford Them and How Should we use
them Before and After Liver Transplantation. Alberta Society of
Gastroenterology, Lake Louise, Alberta.
2015 Vanguard Grand Round Case Presentation. International Liver Transplant
Society, Chicago, Illinois
2018 Hepatitis C Elimination. The 15th National Congress of Chinese Society of
Infectious Disease. Beijing, China
Saab 28
2019 New Insights into the Viral Hepatitis Managements. Goals Beyond
Achieving the Goals of Chronic Hepatitis B Therapy. Hong Kong
Association for the Study of Liver Diseases, Hong Kong, China.
2019 Middle East Liver Forum. Managing At-Risk Populations with Hepatitis
C: Drug Users and Prisoners (Royal College of Physicians activity).
Dubai, United Arab Emirates.
2019 Middle East Liver Forum. Screening and Linkage to Care: PWIDs and
Others (Royal College of Physicians activity). Dubai, United Arab
Emirates.
Saab 29
PATIENT EDUCATION/MULTIMEDIA
2000 Organs for Life, Live Broadcast, Host, Jerry Reilly
2001 Enfermedades Del Hígado: Los Especialistas Responden (in Spanish)
Symposium Co-director, American Liver Foundation, Los Angeles
Chapter
2002 Enfermedades Del Hígado: Los Especialistas Responden (in Spanish)
American Liver Foundation, Los Angeles Chapter
2002 Viral hepatitis, Latino Issues Forum, Los Angeles
2003 Enfermedades Del Hígado (in Spanish) Symposium Co-director,
University of California Los Angeles
2003 La Hepatitis C, Public Service Announcement, Radio Super Estrella 107.1
FM
2003 Doctors: Diet Supplement May Harm Liver, NBC Nightly Television
News
2003 Un padecimiento que no se siente, La Opinion (in Spanish)
2003 Liver damage and cirrhosis, NBC Nightly Television News
2004 Liver Diseases, Symposium Director, University of California Los
Angeles Medical Center and the American Liver Foundation, Los Angeles
Chapter
2004 Breaking Point: Danger and Diet, Fox News
2004 La Hepatitis C, Public Service Announcement, Radio Super Estrella 107.1
FM
2004 Hepatitis C Overview, Hepatitis C Summit, Hepatitis C Task Force for
Los Angeles County
2004 Protect your Liver and Pancreas (in English and Spanish), Community
Seminar, Research Center for Alcohol Liver and Pancreatic Diseases, Los
Angeles
2004 Acetaminophen toxicity, Live Interview , Max Aub,
“Hoy por Hoy” for W Radio XETRA 690AM (in Spanish)
2005 Liver Disease Update, Symposium Director, University of California Los
Angeles Medical Center and the American Liver Foundation, Los Angeles
Chapter
2005 Knowing your Liver, Kiwanis Organization, Downey, California
2005 Enfermedades Del Hígado (in Spanish), Symposium Co-director,
University of California Los Angeles
2006 Liver Diseases Update, Symposium Director and Speaker, University of
California Los Angeles Medical Center and the American Liver
Foundation, Los Angeles Chapter
2006 Liver Diseases among Latinos, Live Interview, Juan Carlos Show, Radio
Super 830 AM (in Spanish)
2007 Liver Diseases Update. Symposium Director and Speaker, University of
California Los Angeles Medical Center and the American Liver
Foundation
2007 Hepatitis C. Live Panel, Seventh Annual KLJH Women’s Health Forum,
KLJH 102.3FM
2007 Hepatitis C and Alcohol. Alcohol and Your Health - 4th Annual
Community Seminar, Los Angeles, University of Southern California
Saab 30
2007 “A Silent Disease that Speaks Volumes”. Article in Westlake Magazine
October/November 2007; page 80.
2008 “Palisades Expert Warns about Liver Disease”. Article in Palisadian-Post
January 2008.
2008 La Hepatitis C. Aquí y Ahora for Univision Television Station (in
Spanish)
2008 Liver Diseases Update. Symposium Director and Speaker, University of
California Los Angeles Medical Center and the American Liver
Foundation
2008 Hepatitis C: Diagnosis and Management. Liver Wellness. Liver Health
and Disease Prevention. Los Angeles, California
2008 What the Liver Does. Moving Mountains. Sacramento, California
2009 Want to be a Doctor? Korean PBS, Airs in South Korea
2009 Liver Diseases – Update on Diagnosis, Complications, and
Management. Symposium Director, University of California Los Angeles
Medical Center
2010 What your liver can do for you! Corpus Christi School, Pacific Palisades,
California
2010 Liver Diseases – Update on Diagnosis, Complications, and
Management. Symposium Director, University of California Los Angeles
Medical Center
2010 Viral hepatitis, alcohol, and liver transplantation. USC Institute for
Health Promotion and Disease Prevention Research. Alhambra, California
2011 Department of Medicine Grand Rounds ~ Management of Cirrhosis, and
its Complications (CME activity) ~ Providence Holy Cross Medical
Center, California
2011 Best Practices for the Management of Hepatitis C: Screening,
Linkage to Care, and Treatment (CME activity). Association of Black
Woman Physicians, West Hollywood, California
2011 Hepatitis B: From Diagnosis to Treatment (CME activity) ~ Moving
Mountains Redding, California
2011 A Future in Health Care ~ UCLA American Medical Women’s
Association ~Los Angeles, CA
2011 Hepatitis C. Knowledge is Power. K-Power 105.9 ~ Los Angeles, CA
2012 Liver Diseases – What the Liver Can do for You! Speaker and
Symposium Director, University of California Los Angeles Medical
Center
2013 Liver and Hepatitis: Advances in Hepatitis C Treatment Strategies:
Understanding Patient Care and New Drugs. Los Angeles, California.
2014 Hepatitis C drug worth the price: Opposing View. July 16, 2014
USA Today (op-ed)
2014 Liver Diseases Update. Symposium Director and Speaker, University of
California Los Angeles Medical Center and the American Liver
Foundation
2014 Hepatitis C: Management, Treatment Strategies and New Drugs for
Cure. St Anne’s. Los Angeles, California.
2014 Advances in Hepatitis C Management and Treatment. Loudermilk
Center, Atlanta, Georgia
Saab 31
2014 Strategies in Hepatitis C. https://smp.newshq.businesswire.com/node/1065
2014 Liver Interview on Hepatitis C , Doctor Radio, Sirius XM 81.
2015 Hepatitis C: Are you at Risk. Healthafter50. Health Advice from
America’s Leading Doctors ~ Scientific American Consumer Health.
Issue September 2015. Page 6.
2015 HCV at a Crossroad: The Pre- or Post-Transplant Treatment Debate.
HCVnext. 2015:9-15
2015 Liver Diseases Update 2015. Symposium Director and Speaker,
University of California Los Angeles Medical Center, Los Angeles,
California
2016 New Hepatitis C Drug is a Game Changer. Bottom Line. On the news.
Bottom Line Personal publication.
2016 Hepatitis Awareness. Hepatitis C Screening. St John Coptic
Orthodox Church. Covina, California.
2016 Hepatitis Awareness Month. Hepatitis C Screening. St Peter and Paul
Coptic Orthodox Church. Santa Monica, California
2016 World Hepatitis Day Press Conference, Emcee, St Vincent Medical
Center, Los Angeles, California
2016 Hepatitis Awareness. Hepatitis C Screening. Archangel Michael
Coptic Orthodox Church. Santa Ana, California
2016 14th Annual Hepatitis C Summit. Understanding New HCV
Treatment Options. Los Angeles, California
2017 American Liver Foundation Ask the Experts Seminar: Update on Viral
Hepatitis B and C. Culver City, California
2017 Liver Diseases – Update on Diagnosis, Complications, and
Management. Symposium Director, University of California Los Angeles
Medical Center, Los Angeles, California
2017 Hepatitis C: Final Countdown, St Anne’s Conference Center. Los Angeles,
California.
2018 Current Trends in Liver Cancer. KNX1070 News. Los Angeles, California
2018 Liver Diseases – Alcohol Liver Disease. Patient Symposium Director,
University of California Los Angeles Medical Center, Los Angeles,
California
2018 Hepatitis C: Working Toward Elimination. St Anne’s Conference Center.
Los Angeles, California
2018 12th Annual UCLA Liver Diseases Symposium ~ Treatment and
Epidemiology of Hepatitis C Infection, Present, and Future (CME activity)
~ University of California Los Angeles, Pasadena, California
2018 Chairperson, American Liver Foundation. 11th Annual Liver Life Walk
Los Angeles. Santa Monica, California
2018 Hepatitis B Reactivation in Patients Treated for Hepatitis C.
Consultant360 Podcast
2019 Hepatocellular Carcinoma. Patient Symposium Director, Ronald Reagan
Medical Center, University of California Los Angeles, Los Angeles,
California
2019 Obesity and Fatty Liver Disease: The Link Between Metabolic Disorders
and NASH. HealthWell Foundation.
Saab 32
http://www.realworldhealthcare.org/2019/09/obesity-and-fatty-liver-
disease-the-link-between-metabolic-disorders-and-nash/
2019 Coronavirus Overview for Liver Disease Patients & Caregivers. American
Liver Foundation.
2020 Covid-19 and the Liver. American Liver Foundation Live Webcast.
Saab 33
PUBLICATIONS
A. RESEARCH PAPERS - PEER REVIEWED
1. Silva JA, Leong GB, Saab S, Wine DB. Misidentification syndromes; facial
misrecognition and dysmorphic symptoms. Psychosomatics 1992; 33:471-472.
2. Silva JA, Leong GB, Wine DB, Saab S. Evolving misidentification syndromes and
facial misrecognition deficits. Can J Psychiatry 1992; 37:574-576.
3. Saab S, Rickman LS, Lyche KD. Ascites and the acquired immunodeficiency syndrome:
report of fifty-four cases. Medicine 1996; 75:131-141.
4. Saab S, Venkataramani A, Behling CA, Savides TJ. Gastric mucosal calcinosis in a
patient with dyspepsia. J Clin Gastroenterol 1996;22:156-157.
5. Saab S, Venkataramani A, Yao F. Possible granulomatous hepatitis following
dicloxacillin therapy. J Clin Gastroenterol 1996;22:163-164.
6. Saab S, Rickman LS. Diagnostic features of tuberculous peritonitis. Am J Med
1996;101:568-569.
7. Saab S, Yao F. Fibrolamellar hepatocellular carcinoma: case reports and a review of the
literature. Dig Dis Sci 1996;41:1981-1988.
8. Ruiz MA, Saab S, Rickman LS. The clinical detection of scleral icterus: observations of
multiple examiners. Military Medicine 1997;162:560-563.
9. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-
Sulfamethoxazole induced vanishing bile duct syndrome. Am J Gastroenterol
1997;92:167-9
10. Tucker WN, Saab S, Rickman LS, Mathews WC. The scratch test is unreliable for
detecting the liver edge. J Clin Gastroenterol 1997;25:410-414.
11. Saab S, Corr MP, Weisman MH. Corticosteroids and systemic lupus erythematosus
pancreatitis? Case series and review of the literature. J Rheumatol 1998;25:801-806.
12. Saab S, Martin P. Tests for acute and chronic viral hepatitis. Postgrad Med
2000;107:123-34.
13. Leopoldt D, Yee HF Jr, Saab S, Rozengurt E. Dissociation of tyrosine phosphorylation
of p125Fak, p130Cas and paxillin from ERK activation in Swiss 3T3 cells stimulated by
bombesin or platelet-derived growth factor. J Cell Physiol 2000;183:208-220.
14. Saab S, Soliman GY, Han SH, Machicado GA, Roth BE, Kunder G, Farmer DG,
Ghobrial RM, Martin P, Busuttil RW, Bedford RA. Endoscopic management of biliary
leaks following t-tube removal in liver transplant recipients: nasobiliary drainage vs
biliary stenting. Liv Transpl 2000;6:627-632.
15. Saab S, Martin P, Yee HF Jr. A simple cost-decision analysis model for comparing two
strategies for hepatitis A vaccination. Am J Med 2000;109:241-244.
16. Saab S, Martin P, Han SHB, Kim M, Wright TL, Busuttil RW. Successful orthotopic
liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus.
Gastroenterol 2000;119:1382-1384.
17. Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Serum alanine aminotransferase in
hepatitis C screening of patients on hemodialysis. Am J Kid Dis 2001;37:308-315.
18. Saab S, Brezina M, Gitnick G, Martin P, Yee HF Jr. Hepatitis C antibody based testing is
the preferred strategy for hepatitis C screening in hemodialysis patients. Am J Kid Dis
2001;38:91-97.
19. Shimoda M, Saab S, Ghobrial RM, Farmer DG, Han SHB, Bedford RA, Goldstein LI,
Martin P, Busuttil RW. A cost-effective analysis of biliary anastomosis with or without
T-tube after orthotopic liver transplantation. Am J Transpl 2001;1:157-161.
Saab 34
20. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, Farmer DG,
Yersiz H, Danino N, Collisson E, Baquarizo A, Han S, Saab S, Goldstein LI, Donovan
JA, Esrason K, Busuttil RW. A 10-year experience of liver transplantation for hepatitis c:
analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-
394.
21. Ly D, Yee HF Jr, Martin P, Brezina M, Gitnick G, Saab S. Hepatitis B immunization
causes detectable hepatitis B surface antigen in hemodialysis patients. Am J
Gastroenterol 2002;97:138-141.
22. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW,
Farmer DG, Yersiz H, Baquerizo A, Geevarghese S, Han SH, Goldstein L, Holt CD,
Gornbein JA, Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year
single-center experience. Ann Surg 2002;235:611-20.
23. Saab S, Ly D, Lin R, Rojter SE, Han S, Ghobrial RM, Busuttil RW. Cost-effectiveness
of treating hepatitis C after liver transplantation. Liv Transpl 2002;8:449-57.
24. Saab S, Weston S, Ly D, Brezina M, Yee HF Jr, Han S, Gitnick G. A cost-effective
decision analysis model comparing two strategies for hepatitis B immunity in the
hemodialysis community. Vaccine 2002;20:3230-3235.
25. Ghobrial RM, Gornbein J, Steadman R, Danino N, Markmann JF, Holt C, Anselmo D,
Amersi F, Chen P, Farmer DG, Han S, Derazo F, Saab S, Goldstein LI, McDiarmid SV,
Busuttil RW. Pretransplant Model to Predict Posttransplant Survival in Liver Transplant
Patients. Ann Surg 2002;236:315-323.
26. Ghobrial RM, Saab S, Lassman C, Lu DS, Raman S, Limanond P, Kunder G, Marks K,
Amersi F, Anselmo D, Chen P, Farmer D, Han S, Durazo F, Goldstein LI, Busuttil RW.
Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver
Transpl 2002;8:901-9.
27. Nyamathi A, Robbins WA, Fahey JL, Wiley D, Pekler VA, Longshore D, Robins TA,
Singh J, Saab S. Presence and predictors of hepatitis C virus RNA in the semen of
homeless men. Biol Res Nurs 2002;4:22-30.
28. Saab, S, Tam SP, Tran BN, Melton AC, Tangkijvanich, P, Wong HC, Yee, Jr HF.
Myosin mediates contractile force generation by hepatic stellate cells in response to
endothelin-1. J Biomed Sci, 2002;9:607-12.
29. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, Saab S, Durazo F, Goldstein
L, Farmer D, Ghobrial RM, Busuttil RW. Conversion from intravenous to intramuscular
hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in
patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver
transplantation. Liver Transpl 2003;9:182-7.
30. Saab S, Hu R, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H,
Ghobrial RM, Farmer DG, Busuttil RW, Lassman C. Discordance between alanine
aminotransferase and liver histology in liver transplant recipients treated with ribavirin
for recurrent hepatitis C infection. Am J Transpl 2003;3:328-33.
31. Tang SJ, Geevarghese S, Saab S, Martinez D, Van Herle A, Wallace WD, Cortina GR,
Dry S, Busuttil RW. A parathyroid hormone-related protein-secreting metastatic
epithelioid leiomyosarcoma. A case report and review of the literature. Arch Pathol Lab
Med 2003;127:181-5.
32. Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M,
Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein L, Holt C, Busuttil
RW. Liver transplantation for fulminant hepatic failure: experience with more than 200
patients over a 17-year period. Ann Surg 2003;237:666-76.
Saab 35
33. Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B. Cost and clinical outcomes of
primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision
analytic model. Am J Gastroenterol 2003;98:763-70.
34. Saab S, Wang V, Ibrahim AB, Morrisey M, Durazo F, Han, S, Kunder G, Durazo F,
Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil RW. MELD score as a
predictor of post-orthotopic liver transplantation one-year patient and graft survival. Liver
Transpl 2003;9:473-6.
35. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Durazo F, Han, S, Kunder G, Durazo F, Yersiz
H, Ghobrial RM, Farmer DG, Amado R, Goldstein LI, Tong M, Busuttil RW.
Hepatocellular carcinoma screening in patients waiting for liver transplantation: A
decision analytic model. Liver Transpl 2003;9:672-81. With accompanying editorial.
36. Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, Farmer DG, Yersiz H,
Goldstein LI, Busuttil RW.. Hepatitis C positive grafts may be used in orthotopic liver
transplantation: a matched analysis Am J Transpl 2003;3: 1167-72. With accompanying
editorial.
37. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for
US college students. J Am Col Health 2003;51:227-236.
38. Saab S, Chang A, Comulada S, Geeverghese SK, Anselmo DM, Kunder G, Durazo F,
Han, S, Kunder G, Durazo F, Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil
RW. Outcomes of hepatitis C and hepatitis B core antibody positive grafts in orthotopic
liver transplantation. Liver Transpl 2003;9:1053-1061.
39. Jacobs RJ, Greenberg DP, Koff R, Saab S, Meyerhoff AS. Regional variation in the
cost-effectiveness of childhood hepatitis A immunization. Ped Infect Dis J 2003;22:904-
914.
40. Jacobs RJ, Saab S, Meyerhoff AS, Koff R. An economic assessment of pre-
immunization screening for hepatitis A and B. Public Health Reports 2003;118:550-8.
41. Ghobrial RM, Saab S, Lassman C, Lu DSK, Raman S, Limanond P, Kunder G, Marks K,
Amersi F, Anselmo D, Chen P, Farmer d, Han S, Durazo F, Goldstein LI, Busuttil RW.
Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver
Transpl 2003;8:901-909.
42. Kanwal F, Chen D, Ting L, Gornbein J, Saab S, Durazo F, Yersiz H, Farmer D, Ghobrial
RM, Busuttil RW, Han SH. A model to predict the development of mental status changes
of unclear cause after liver transplantation. Liver Transpl 2003;9:1312-9.
43. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu
DS. Macrovesicular hepatic steatosis in living related liver donors: Correlation between
CT and histologic findings. Radiology. 2004;230:276-280.
44. Yao FY, Saab S, Bass NB, Hirose r, David Ly, Terrault N, Lazar AA, Bacchetti P,
Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft
failure based on preoperative prognostic scores. Hepatology 2004;39:230-8.
45. Limanond P, Raman SS, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Preoperative
imaging in adult-to-adult living related liver transplant donors: what surgeons want to
know. J Comput Assist Tomogr. 2004;28:149-157.
46. Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S,
Farmer DG, Yersiz H, Goldstein RL, Ghobrial M, Busuttil RW. Fulminant liver failure
due to usnic Acid for weight loss. Am J Gastroenterol. 2004;99:950-2.
47. Saab S, Nieto J, Ly D, Runyon B. TIPS versus paracentesis for cirrhotic patients with
refractory ascites. The CLib Issue 3, 2004.
Saab 36
48. Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersi
H, Goldstein LI, Lassman CL, Busuttil RW. Outcomes of acute rejection after interferon
therapy in liver transplant recipients. Liver Transpl 2004;10:859-67. With
accompanying editorial.
49. Saab S, Ibrahim AB, Lee C, Shpaner A. Seroepidemiology of hepatitis A in patients
with chronic liver disease. J Viral Hepatitis 2004;11:101-5.
50. Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P,
Dawson S, Durazo F, Han S, Goldstein LI, Saab S, Hiatt J, Busuttil RW. Predictors of
survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis
C. Liver Transpl. 2004;10:1478-1486.
51. Saab S, Cho D, Quon D, Ibrahim AI, Dong P, Marder V, Logan L. Same day outpatient
transjugular liver biopsies in hemophilia. Haemophilia 2004;10:727-737.
52. Ibrahim AB, Shpaner A, Nieto J, Saab S. Liver fibrosis is accelerated in HIV/HCV
coinfection: a matched analysis. SA Gastroenterol Rev 2004;2:14-17.
53. Saab S, Cho D, Gajjar NA, Ghobrial RM, Lassman CL, Busuttil RW. Recurrent NASH
in a living related liver transplant recipient. J Hepatol 2005;42:148-9.
54. Saab S, Ibrahim AB, Shpaner A, Lee C, Durazo F, Han S, Esrason K, Wu V, Hiatt J,
Farmer DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong M, Busuttil RW.
Association between liver disease severity and quality of life in liver transplant
candidates. Liver Transpl 2005;11:218-223. With accompanying editorial.
55. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S,
Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular
carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137.
56. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, Saab S, Han
S, Durazo F, Weaver M, Cao C, Chen T, Lipshutz GS, Holt C, Gordon S, Gornbein J,
Amersi F, Ghobrial RM. Analysis of Long-term Outcomes of 3200 Liver
Transplantations Over Two Decades: A Single-Center Experience. Ann Surg.
2005;241:905-918.
57. Jacobs RJ, Meyerhoff AS, Saab S. Immunization needs of chronic liver disease patients
seen in primary care versus specialist settings. Dig Dis Sci 2005;50:1525-31.
58. Saab S, Niho H, Comulada S, Hiatt J, Durazo F, Han S, Kunder G, Yersiz H, Farmer
DG, Goldstein LI, Ghobrial RM, Busuttil RW. Mortality predictors in liver transplant
recipients with recurrent hepatitis C cirrhosis. Liver Int. 2005;25:940-5.
59. Saab S, Nguyen S, Ibrahim A, Vierling JM, Tong MJ. Management of patients with
cirrhosis in Southern California: results of a practitioner survey. J Clin Gastroenterol
2006;40:156-61.
60. Shiffman ML, S Saab, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, Schaubel DE.
The 2005 SRTR Report on the State of Transplantation: Liver and Intestine
Transplantation in the United States, 1995-2004. Am J Transplant 2006;6:1170-87.
61. Biggins S, Kim WR, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W,
Wiesner R, Kamath P, Terrault N. MELDS: Incorporation of the serum sodium
concentration into MELD: An evidence-based proposal. Gastroenterology
2006;130:1652-60.
62. Saab S, Landaverde C, Ibrahim A, Durazo F, Han S, Farmer DG, Ghobrial M, Holt C,
Yersiz H, Goldstein L, Lipshutz G, Tong MJ, Busuttil RW. Predictors of mortality and
MELD scores changes while waiting for liver transplantation. Experimental and Clinical
Transpl 2006;1:395-9.
Saab 37
63. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, Esrason K, Wu V, Hiatt J, Farmer
DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong M, Busuttil RW. Prevalence
and risk factors for diabetes mellitus in liver transplant recipients. Am J Transpl
2006;6:1890-5.
64. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, Yersiz H,
Zimmerman MA, Durazo F, Han SH, Saab S, Gornbein J, Busuttil RW. Effect of
Nonviral Factors on Hepatitis C Recurrence After Liver Transplantation. Ann Surg.
2006;244:563-571.
65. Saab S, Nieto J, Lewis S, Runyon B. TIPS versus paracentesis for cirrhotic patients with
refractory ascites. The CLib Issue 3, 2006.
66. Terrault NA, Shiffman ML, Lok ASF, Saab S, Gillespie BW, Brown RS, Everson GT,
Reddy KR, Farr JH,Kulik LM, Pruett TL, Seeff LB and the A2ALL Study Group. Graft
Survival in Hepatitis C Virus Infected Recipients of Living Donor Liver Transplantation
Versus Deceased-Donor Liver Transplantation. Liver Transpl 2006;13:122-129
67. Saab S, Nguyen S, Collins J, Kunder G, Busuttil RW. Contribution of lymphedema tarda
to chylous ascites after liver transplantation: Case report and review of the literature.
Experimental and Clinical Transpl Exp Clin Transplant. 2006;4:567-70.
68. Otsuka Y, Duffy JP, Saab S, MD, Farmer DG, Ghobrial RM, Hiatt JR, Busuttil RW.
Post-Resection hepatic failure: successful treatment with liver transplantation. Liver
Transpl 2007;13:672-9.
69. Trotter JF, Hill-Callahan MM, Gillespie BW, Nielsen C, Saab S, Shrestha R, Talamantes
MM, Weinrieb RM, and the A2ALL Study Group. Severe psychiatric problems in right
hepatic lobe donors for living donor liver transplantation. Transpl 2007 83:1506-1508.
70. Kim A, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-
infected patients: a meta-analysis. HIV Med 2007;8:312-21.
71. Saab S, Mina Oh, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,
Goldstein LI, Tong MJ, Busuttil RW Risk factors for anemia in live transplant recipients
being treated for recurrent hepatitis C. Liver Transpl 2007;13:1032-8.
72. Saab S, Wiese C, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,
Goldstein LI, Tong MJ, Busuttil RW. Employment and quality of life in liver transplant
recipients. Liver Transpl 2007; 13: 1330-8.
73. Saab S, Dong M, Joseph T, Tong M. Hepatitis B prophylaxis in patients undergoing
chemotherapy for lymphoma: A decision analysis model. Hepatology. 2007;46:1049-56.
74. Trotter JF, Wisniewski KA, Terrault NA, Kinkhabwala M, Weinrieb RM, Fair JH, Fisher
RA, Koffron AJ, Saab S, Merion RM, and the A2ALL Study Group. Outcomes of donor
evaluation in adult-to-adult living donor liver transplantation. Hepatology 2007;46:1476-
84.
75. Martyak LA, Taqavi E, Saab S. Lamivudine Prophylaxis for Hepatitis B Reactivation in
Patients Undergoing Cytotoxic Chemotherapy: A Systematic Review. Liver International
2008;28:28-38.
76. Yuan Y, Iloeje UH, Hay J, Saab S. An Evaluation of the Cost Effectiveness of Entecavir
versus Lamivudine in suppressing viral replication in Hepatitis BeAg-positive Chronic
Hepatitis B (CHB) Patients. J Managed Care Pharmacy. 2008;14:21-33.
77. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-
gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic
hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol.
2008;23:1541-8.
Saab 38
78. Saab S, Ibrahim AB, Surit B, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,
Goldstein LI, Tong MJ, Busuttil RW Pre-transplant variables associated with qualify of
life in liver transplant recipients. Liver International 2008;28:1087-94.
79. Tan J, Joseph T, Saab S. Treating Hepatitis C in the Prison Population is Cost-Saving.
Hepatology 2008;48:1387-95.
80. Shim M, Saab S. Severe hepatotoxicity due to hydroxycut: A case report. Dig Dis Sci.
2009;54:406-8.
81. Nyamathi AM, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, Leake B, Tyler D,
Gelberg L. Effects of a Nurse Managed Program on Hepatitis Vaccine Completion
among Homeless Adults. Nursing Research 2008 2009;58:13-22.
82. Kanwal F, Spiegel BMR, Hays RD, Durazo F, Han, SB, Saab S, Bolus R, Kim SJ,
Gralnek IM. Prospective Validation of the Short Form Liver Disease Quality of Life
Instrument (The SF-LDQOL). Aliment Pharmacol Ther. 2008;28:1088-101.
83. Campsen J, Blei AT, Emond JC, Everhat JE, Freise CE, Lok AS, Saab S, Wisniewski
KA, Trotter JD, Adult to Adult Living Donor Liver Transplantation Cohort Study Group.
Outcomes of living donor liver transplantation for acute liver failure: The adult-to-adult
living donor liver transplantation cohort study. Liver Transpl. 2008;14:1273-1280.
84. Nyamathi A, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, Leake B, Tyler D,
Gelberg L. Effects of a Nurse-Managed Program on Hepatitis A and B Vaccine
Completion Among Homeless Adults. Nurs Res. 2009;58:13-22.
85. Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, Han SH, Durazo FD, Saab S, Blatt
LM. Factors Associated with Progression to Hepatocellular Carcinoma and to Death
from Liver Complications in Patients with HBsAg-Positive Cirrhosis. Dig Dis Sci
2009;54:1337-46.
86. Feasibility of Completing an Accelerated Vaccine Series for Homeless Adults. Nyamathi
AM, Sinha K, Saab S, Marfisee M, Greengold B, Leake B, Tyler D. J Viral Hepat.
2009;16:666-73.
87. Tabibian JH, Asham EH, Goldstein L, Han SH, Saab S, Tong MJ, Busuttil RW, Durazo
FA. Endoscopic treatment with multiple stents for post-liver-transplantation
nonanastomotic Biliary strictures. Gastrointest Endosc. 2009;69:1236-43.
88. Saab S, Hernandez JC, Chi AC, Tong. Spontaneous Bacterial Peritonitis Prophylaxis
Improves Morbidity and Mortality: A Meta-Analysis. Am J Gastroenterol 2009;104:993-
1001.
89. Saab S, Ham M, Stone M, Tong M. Decision-Analysis Model on Hepatitis B Prophylaxis
in Liver Transplant Recipients. Liver Transpl 2009;15:413-20.
90. Kanwal F, Gralnek IM, Hays RD, Zeringue A, Durazo F, Han SB, Saab S, Bolus R,
Spiegel BMR. Health-related quality of life predicts mortality in patients with advanced
chronic liver disease. Clin Gastroenterol Hepatol. 2009;7:793-9.
91. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI,
Tong MJ, Busuttil RW. Recurrence of Hepatocellular Carcinoma and Hepatitis B
Reinfection in HBsAg Positive Patients after Liver Transplantation. Liver Transpl
2009;15:1525-34.
92. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary
lesion in a liver transplant recipient treated with sorafenib. Am J Transplant.
2009;9:2851-4.
93. Tabibian JH, Asham EH, Han S, Saab S, Tong MJ, Goldstein L, Busuttil RW, Durazo
FA. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary
Saab 39
strictures with maximal stent therapy (with video). Gastrointest Endosc. 2010;71:505-
512.
94. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of Different Immunoprophylaxis
Regimens after Liver Transplantation with Hepatitis B Core Antibody Positive Donors: A
Systematic Review. Liver Transpl 2010;16:300-307. With accompanying editorial.
95. Tong MJ, Hsu L, Hsien C, Kao J-H, Durazo FA, Saab S, Blatt LM. A comparison of
hepatitis b viral markers of patients in different clinical stages of chronic infection.
Hepatol Int. 2010;4:516-22.
96. Saab S, Hunt D, Stone MA, McClune A, Tong MJ. Timing of Hepatitis C Antiviral
Therapy Pre and Post Liver Transplantation: A Decision Analysis Model. Liver Transpl.
2010;16:748-59: 16:748-59 With accompanying editorial.
97. Duffy JP, Kao K, Ko CY, Farmer DG, McDiarmid SV, Hong JC, Venick RS, Feist S,
Goldstein L, Saab S, Hiatt JR, Busuttil RW. Long-term patient outcome and quality of
life after liver transplantation: analysis of 20-year survivors. Ann Surg. 2010;252:652-61
98. Saab S, McTigue M, Finn R, Busuttil RW. Sorafenib as adjuvant therapy for high risk
Hepatocellular Carcinoma in Liver Transplant Recipients: Feasibility and Efficacy. Exp
Clin Transplant. 2010 Dec;8(4):307-13
99. Foster F, Budoff, MJ, Saab S, Ahmadi N Gordon C, Guerci ID. Atorvastatin and
Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis
Heart Study Randomized Clinical Trial. Am J Gastroenterol. 2011 Jan;106(1):71-7
100. Han SH, Durazo FA, Saab S, Tong MJ. A Proposed, Evidence-based Approach to the
Treatment of Chronic Hepatitis B. J Clin Gastroenterol. 2011;45:259-66.
101. Saab S, Desai S, Tsaoi D, Durazo F, Han SH, McClune A, Holt C, Farmer D, Goldstein
L, Busuttil RW. Post-Transplantation Hepatitis B Prophylaxis with Combination Oral
Nucleoside and Nucleotide Analogue Therapy. Am J Transplant. 2011;11:511-7.
102. Saab S, Bownick H, Ayoub N, Durazo F, Han SH, Farmer D, Hong J, Busuttil RW.
Differences in Health Related Quality of Life Scores after Orthotopic Liver Transplant
with Respect to Selected Socioeconomic Factors. Liver Transpl. 2011;17(5):580-90
103. Saab S, Ng V, Landaverde C, Lee, SJ, Comulada S, Arevalo J, Durazo F, Han SH,
Younossi Z, Busuttil RW. Development of a disease specific questionnaire to measure
health related quality of life in liver transplant recipients. Liver Transpl. 2011;17:567-79
104. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C Virus Infection in the
United States. An Estimated of the True Prevalence. Liver Int. 2011;31:1090-101.
105. Saab S, Ng V, Landaverde C, Lee, SJ, Comulada S, Arevalo J, Durazo F, Han SH,
Younossi Z, Busuttil RW. Development of a disease specific questionnaire to measure
health related quality of life in liver transplant recipients. Liver Transpl 2011;17:567-79.
106. Wertheim J, Kupiec-Weglinski J, Petrowsky H, Saab S, Busuttil, RW. Major challenges
limiting liver transplantation in the United States. Am J Transplant 2011;11:1773-84.
107. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA,
Saab S, Tong MJ, Hiatt JR, Busuttil RW. Comparative analysis of resection and liver
transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a
single center. Arch Surg. 2011;146:683-9.
108. Han SH, Durazo FA, Saab S, Tong MJ A proposed, evidence-based approach to the
treatment of chronic Hepatitis B. J Clin Gastroenterol. 2011;45:259-66.
109. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients
diagnosed with hepatitis C. Clin Ther. 2011;33:1268-80.
Saab 40
110. Chavalitdhamrong D, Jensen DM, Singh B, Kovacs TO, Han SH, Durazo F, Saab S,
Gornbein JA. Capsule Endoscopy Is Not Accurate as Esophagogastroduodenoscopy in
Screening Cirrhotic Patients for Varices. Clin Gastroenterol Hepatol. 2012;10:254-8.
111. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland
TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for Immune-
Mediated Graft Dysfunction in Liver Transplant Recipients with Recurrent HCV
Infection Treated with Pegylated Interferon. Gastroenterology. 2012;142:1132-1139.
112. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr, Saab S, Shiffman ML,
Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE; and the A2ALL Study Group. A
Randomized Controlled Trial of Pretransplant Antiviral Therapy to Prevent Recurrence
of Hepatitis C after Liver Transplantation. Hepatology. 2013; 57:1752-62.
113. Nadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, Feng S,
Friedewald JJ, Hong JC, Kellum JA, Kim WR, Lake JR, Melton LB, Pomfret EA, Saab
S, Genyk YS. Simultaneous Liver-Kidney Transplantation Summit: Current State and
Future Directions. Am J Transplant. 2012; 12:2901-8.
114. Rubin J, Ayoub N, Kaldas F, Saab S. Management of Recurrent Hepatocellular
Carcinoma in Liver Transplant Recipients: A Systematic Review. Exp Clinl Transplant.
2012;10:531-43.
115. Saab S, Choi YM, Rahal H, Li K, Tong M. Trends in Viral Hepatitis Cost-Effectiveness
Studies. Am J Managed Care. 2012;18:790-8.
116. McCombs JS, Yuan Y, Shin J, Saab S. Impact of Drug Therapy Adherence in Patients
with Hepatitis C. Am J Pharmacy Benefits 2012;4 [Special Issue]:SP19-SP27.
117. Sood A, Cox GA, McWilliams JP, Wang HL, Saab S. Patients with Nodular
Regenerative Hyperplasia Should be Considered for Hepatocellular Carcinoma
Screening. Hepatology Research. 2014;44:689-93.
118. Matsuda T, Tonnu-Mihara I, Yuan Y, Hines P, Saab S, Italien GJ, McCombs J. External
validation of the risk-prediction model for hepatocellular carcinoma [hcc] from the reveal
HCV study. Value in Health. 2013;16:A12.
119. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial
M, Kam I, Busuttil R, Saab S, Holt C, Emond J, Stiles J, Lukose T, Chang M, Klintmalm
G. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular
carcinoma in the United States with hepatitis B immunoglobulin and
nucleoside/nucleotide analogues. Liver Transpl. 2013; 19:1020-9.
120. Wai H, Stepanova M, Saab S, Erario M, Srishord M, Younossi ZM. The Inpatient
Economic and Mortality Assessment for Liver Transplantation: A Nationwide Study of
the United States Data from 2005 to 2009. Transplantation. 2014. 15;97:98-103
121. Saab S, Mallam D, Cox GA II, Tong MJ. Impact of Coffee on Liver Diseases: A
Systematic Review. Liver International. 2014;34:495-504.
122. Zhou K, Fergusson J, Bau SN, Saab S. Viral Breakthrough is Associated with Resistance
using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection. J Clin
Gastroenterol 2014; 48:548-52.
123. Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt Cm
Harlander-Locke M, Hon JC, Rana AR, Venick R, McDiarmid SV, Goldstein LI, Durazo
F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW. The Evolution of Liver Transplantation
During 3 Decades. Analysis of 5347 Consecutive Liver Transplants at a Single Center.
Annals of Surgery 2013;258:409-21.
124. Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr, Cameron A,
GhobrialM, Kam I, Busuttil R, Saab S, Holt C, Emond JC, Stiles JB, Lukose T, Chang
Saab 41
MS, Klintmalm G. Multicenter review of liver transplant for hepatitis B-related liver
disease: disparities in gender and ethnicity. Clin Transplant 2013; 27:829-37.
125. Wai H, Stepanova M, Saab S, Erario M, Srishord M, Younossi ZM. Inpatient Economic
and Mortality Assessment for Liver Transplantation: A Nationwide Study of the United
States Data from 2005 to 2009. Transplantation. 2014; 97:98-103.
126. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L'italien G, Juday T, Yuan Y.
The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C:
Results From an Analysis of Data From a Department of Veterans Affairs Clinical
Registry. JAMA Intern Med. 2014;174:204-12.
127. Saab S, Lalezari D, Alper T, Pruthi P, Tong MJ. The Impact of Obesity on Patient
Survival in Liver Transplant Recipients: A Meta-Analysis. Liver Int. 2013 Dec 8. [Epub
ahead of print].
128. Terrault NA, Stravitz RT, Lok ASF, Everson GT, Brown Jr RS, Kulik LM, Olthoff KM,
Saab S, Adeyi O, Argo CK, Everhart JE, Rodrigo DR, A2ALL Study Group. Hepatitis C
disease severity in living versus deceased donor liver transplant recipients: An extended
observation study. Hepatology 2014; 59:1311-1319.
129. Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile Infection in
Patients with Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1745-
52.e2
130. Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M,
Han S, Busuttil RW. Boceprevir in Liver Transplant Recipients. Liver Int. 2014.
131. Saab S, Manne V Akhtar E. Cirrhosis Regression in Hepatitis C Patients with Sustained
Virologic Response after Anti-Viral therapy: A Meta-analysis. Liver International 2014
132. Saab S, Gordon SC, Park H, Ahmed A, Younossi ZM. A decision analytic Markov
model to evaluate the health outcomes of sofosbuvir for previously untreated patients and
those without treatment options with chronic hepatitis C virus. Alimentary Pharmacol
Therapy 2014;40:657-75.
133. Saab S, Manne V, Bui V, Sundaram. Cumulative Radiation Exposure in Liver Transplant
Candidates and Patients Transplanted with Hepatocellular Carcinoma. J Liv Dis
Transplant 2014
134. Choi G, Lee KG, Wu C, Saab S. Kidney Transplantation Threshold in Patients with
Hepatitis C: A Decision Analysis Model. Transplantation 2014
135. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The Portrait of
an Adult Liver Transplant Recipient in the United States From 1987 to 2013. JAMA
Intern Med. 2014;174:1407-9.
136. Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S.
The impact of type 2 diabetes and obesity on the long-term outcomes of more than
85,000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40:686-94.
137. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, Gordon F, O'Leary
J,Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, et al. Sofosbuvir
and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-
label study. Gastroenterology. 2015;148:100-107.
138. Lee EW, Saab S, Gomes AS, Busuttil R, McWilliams J, Durazo F, Han SH, Goldstein L,
Tafti BA, Moriarty J, Loh CT, Kee ST. Coil-Assisted Retrograde Transvenous
Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding:
Preliminary Results. Clin Transl Gastroenterol. 2014;5:e61. doi: 10.1038/ctg.2014.12.
Saab 42
139. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi Z. The outcomes of
adult liver transplants in the united states from 1987 to 2013. Liver Int. 2015;358):2036-
41.
140. Younossi Z, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. The association of
hepatitis C virus infection and post-liver transplant diabetes: data from 17,000 HCV-
infected transplant recipients. Aliment Pharmacol Ther. 2015;41:209-17.
141. Al-hamoudi W, Elsiesy H, Bendahmash A, Al-masri N, Ali S, Allam N, Al Sofayan M,
Al Bahili H, Al Sebayel, Dieter Broering M, Saab S, Abaalkhail F. Liver transplantation
for hepatitis B virus: Decreasing indication and changing trends. W J Gastroenterol
2015;21: 8140-7.
142. Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, Han S, Busuttil RW.
Sofosbuvir and Simeprevir is Effective for Recurrent Hepatitis C in Liver Transplant
Recipients. Liver International 2015;35:2442-7. With accompanying editorial.
143. Saab S, Alper T, Sernas E, Pruthi P, Alper MA, Sundaram V. Hospitalized Patients with
Cirrhosis should be Screened for Clostridium Difficile Colitis. Dig Dis Sciences
2015;60:3124-9.
144. Saab S, Jimenez M, Fong T, Wu C, El Kabany M, Tong MJ. Timing of Antiviral
Therapy in Liver Transplant Candidates listed for Hepatitis C and Hepatocellular
Carcinoma. Exp Clin Transpl 2016;14: 66-71.
145. Al-Hamoudi W, Elsiesy H, Bendahmash A, Al-Masri N, Ali S, Allam N, Al Sofayan M,
Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for
hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol.
2015;21:8140-7
146. Saab S, Jimenez M, Bau S, Goo T, Zhao D, Durazo F, Han S, El Kabany M, Kaldas F,
Tong MJ, Busuttil RW. Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and
Ribavirin: A Matched Analysis. Clin Transplant. 2015; 29: 813-9.
147. Bonham CA, Saab S, Younossi ZM, Ahmed A. HCV Infection is Associated with Lower
Survival in Simultaneous Liver Kidney Transplant Recipients in the U.S. Perumpail RB,
Wong RJ, Scandling JD, Ha LD, Todo T. Clin Transplant. 2015;29:920-6.
148. Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal
radiation therapy on non-conventional liver tumors. World J Gastroenterol.
2015;21:8271-83.
149. Younossi ZM, Stepanova M, Saab S, Ahmed A, Lam B, Srishord M, Venkatesan C, Wai
H, Henry L. The impact of viral hepatitis-related hepatocellular carcinoma to post-
transplant outcomes. J Viral Hepat. 2016: 23: 53-61.
150. Saab S, Suraweera D, Au J, Saab E, Alper T, Tong MJ. Probiotics are Helpful in Hepatic
Encephalopathy: A Meta-Analysis of Randomized Trials. Liver Int 2016;36:986-93.
151. Sheen V, Nguyen H, Jimenez, M, Agopian V, Vangala S, Elashoff D, Saab S. Routine
Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant
Recipients with Chronic Hepatitis C: a 10-Year Experience. J Clin Translational
Hepatol 2016;4:20-5.
152. Lu NT, Crespi CM, Liu NM, Vu JQ, Ahmadieh Y, Wu S, Lin S, McClune A, Durazo F,
Saab S, Han S, Neiman DC, Beaven S, French SW. A Phase I Dose Escalation Study
Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in
Patients with Chronic Hepatitis C. Phytother Res. 2016; 30: 160-8.
153. Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-
transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic
steatohepatitis. BMC Gastroenterol. 2015;15:175.
Saab 43
154. Saab S; Park SH; Mizokami M; Omata M; Mangia A; Eggleton E; Zhu Y et al. Safety
and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in
Subjects Aged 65 Years or Older. Hepatology 2016;63:1112-9.
155. Tonnu-Mihara I, Matsuda T, McCombs, J, Saab S, Hines P, L’Italien G, Juday T, Yuan
Y. Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C:
Veterans Affairs Data from 1999-2010. Universal Journal of Medical Science 2016;4:10-
20.
156. Goring SM, Gustafson P, Liu Y, Saab S, Cline SK, Platt RW. Disconnected by design:
Analytic approach in treatment networks having no common comparator. Research
Synthesis Methods 2016. DOI: 10.1002/jrsm.1204.
157. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L’Italien G, Kalsekar A,
Yuan Y. Using the Fib-4 Score to Monitor Morbidity and Mortality Risk in Chronic
Hepatitis C Patients. J Virol Retrovirol 2016; 2: 1-10.
158. Duminda S, Jimenez M, Viramontes M, Naadir J, Grotts J, Elashoff D, Lee E, Saab S.
Age-Related Morbidity and Mortality after Transjugular Intrahepatic Portosystemic
Shunts. J Clin Gastroenterol 2017; 51: 360-363.
159. Molski C, Sarria EE, Mattiello R, Saab S, Medeiros R, Brandão A. Cultural validation of
the post-Liver transplant quality of life (pLTQ) questionnaire for the Brazilian
population. Ann Hepatol 2016;15:377-385.
160. Saab S, Rheem J, Jimenez M, Bau S, Choi G, Durazo F, El Kabany M, Han S, Farid A,
Jamal N, Grotts J, Elashoff D, Busuttil RW. Curing Hepatitis C in Liver Transplant
Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl
Hepatol. 2016;4:32-8.
161. Saab S, Parisé H, Virabhak S, Wang A, Marx SE, Sanchez Gonzalez Y, Misurski D,
Johnson S. Cost-effectiveness of currently recommended direct-acting antiviral
treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the United
States. J Med Econ. 2016;8:795-805.
162. Saab S, Jimenez M, Fong T, Wu C, Bau S, Grotts J, Elashoff D. Accessibility to Oral
Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin
Transl Hepatol. 2016;4:76-82.
163. Elrazek AE, Amer M, Hawary B, Salah A, Bhagavathula AS, Al Boraie M, Saab S.
Prediction of HCV vertical transmission: What are factors should be optimized using data
mining computational analysis. Liver Int. 2017; 37: 529-533.
164. Saab S, Jimenez M, Bau S, Choi G, Durazo F, El Kabany M, Han SB, Busuttil RW. Use
of Sofosbuvir- Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on
Hemodialysis. J Clin Gastroenterol 2016; 51: 167-173.
165. Koenig A, Stepanova M, Saab S, Ahmed A, Wong R, Younossi ZM. Long-term
outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of
the U.S. transplant registry. Aliment Pharmacol Ther. 2016; 44: 271-8.
166. Younossi ZM, Park H, Gordon SC, Ferguson JR, Ahmed A, Dieterich D, Saab S. Real-
world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am
J Manag Care. 2016 May;22(6 Spec No.):SP205-1.
167. Saab S, Virabhak S, Parise H, Johnson S, Wang A, Misurski D, Gonzalez YS, Juday T.
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients
Coinfected with Human Immunodeficiency Virus in the United States. Adv Ther
2016;33:1-42.
168. Young K, Aguilar M, Gish R, Younossi Z, Saab S, Bhuket T, Liu B, Ahmed A, Wong
RJ. Lower Rates of Receiving Model for End-Stage Liver Disease Exception and Longer
Saab 44
Time to Transplant Among Non-Alcoholic Steatohepatitis Hepatocellular Carcinoma.
Liver Transpl. 2016;22:1356-66.
169. Kuei A, Lee EW, Saab S, Busuttil RW, Durazo F, Han SH, ElKabany M, McWilliams
JP, Kee ST. Inpatient Cost Assessment of Transjugular Intrahepatic Portosystemic Shunt
in the USA from 2001 to 2012. Dig Dis Sci. 2016;61: 2838-2846.
170. Lee EW, Kuei A, Saab S, Busuttil RW, Durazo F, Han SH, El-Kabany MM, McWilliams
JP, Kee ST. Nationwide trends and predictors of inpatient mortality in 83884 transjugular
intrahepatic portosystemic shunt. World J Gastroenterol. 2016;22:5780-9.
171. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of Cost
of Innovation versus the Value of Health Gains Associated with Treatment of Chronic
Hepatitis C in the United States: The Quality-Adjusted Cost of Care. Medicine.
2016;95(41):e5048.
172. May FP, Rolston VS, Tapper EB, Lakshmanan A, Saab S, Sundaram V. The impact of
race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-
sectional study. BMC Gastroenterol. 2016; 16(1): 129.
173. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The Value of Cure
Associated with Treating Treatment-naive Chronic Hepatitis C Genotype 1: Are the New
All Oral Regimens Good Value to Society? Liver Int. 2017;37:662-668.
174. Saab S, Konyn PG, Viramontes MR, Jimenez MA, Grotts, JF, Hamidzadah W, Dang VP,
Esmailzadeh NL, Choi G, Durazo FA, El-Kabany MM, Han SHB, Tong MJ. Limited
knowledge of acetaminophen in patients with liver disease. Journal of Clinical and
Translational Hepatology 2016; 4:281-287.
175. Younossi ZM, Gordon SC, Ahmed A, Dieterich D, Saab S, Beckerman R. Treating
Medicaid Patients with Hepatitis C: Clinical and Economic Impact. A J Managed Care.
2017;23:294-299.
176. Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G,
Durazo FA, El-Kabany MM, Han SHB, Saab S. Decrease of Alpha-Fetoprotein in
Patients with Cirrhosis Treated with Direct Acting Agents. J Clin Transl Hepatol
2017;5:43-49.
177. Patel AA, Walling AM, May FP, Saab S, Wenger N. Palliative Care and Healthcare
Utilization for Patients with End-Stage Liver Disease at the End of Life. Clin
Gastroenterol Hepatol. 2017;15:1612-1619.
178. Lin TY, Shekar AO, Li N, Yeh MW, Saab S, Wilson M, Leung AM Incidence of
Abnormal Liver Biochemical Tests in Hyperthyroidism. Clin Endocrinol (Oxf). 2017;
86:755-759.
179. Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, Saab S, Beckerman
R, Younossi ZM. Treatment of Patients Waitlisted for Liver Transplant with an All-Oral
DAAs is a Cost-Effective Treatment Strategy in the United States. Hepatology
2017;66:46-56.
180. Younossi Z, Gordon SC, Ahmed A, Dieterich D, Saab S, Beckerman R. Treating
Medicaid patients with hepatitis C: clinical and economic impact. Am J Manag Care.
2017;23:107-112.
181. Saab S, Rheem J, Jimenez MA, Fong TM, Mai MM, Kachardoorian CA, Esmilzadeh
NL, Bau SN, Kang S, Ramirez SD, Grotts, Choi G, Durazo FA, El-Kabany MM, Han
SHB, Busuttil RW. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavirin in
Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol 2017;5:101-108.
182. Saab S, Phan J, Jimenez M, Grotts J, Walters L, Hathaway K, Patel K, Lankarani A,
Herman M, Holloman D, Nieto J. Endoscopic Ultrasound Liver Biopsies Accurately
Saab 45
Predict the Presence of Fibrosis in Patients with Fatty Liver. Clin Gastroenterol Hepatol
2017;15:1477-1478.
183. Elrazek A, Saab S, Foad M, Elgohary EA, Sallam MM, Nawara A, Ismael A, et al.
Ongoing transmission of HCV: Should cesarean section be justified? Data mining
discovery. J Transl Int Med. 2017;5:27-33.
184. Stepanova M, Clement S, Wong R, Saab S, Ahmed A, Younossi ZM. Patients with
Diabetes and Chronic Liver Disease are at Increased Risk for Overall Mortality: A
Population Study from the United States. Clinical Diabetes 2017;35:79-83.
185. Aby E, Jimenez MA, Grotts JF, Agopian V French SW, Busuttil RW, Saab S.
Diminishing Role of Liver Biopsy for Hepatitis C in Liver Transplant Recipients. J Clin
Transl Hepatol 2017; 5:197-202.
186. Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ.
Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to
Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181.
187. Castrejón M, Chew KW, Javanbakht M, Humphries R, Saab S, Klausner JD.
Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to
Care Program for Baby Boomers. Open Forum Infect Dis. 2017;4(3):ofx109. doi:
10.1093/ofid/ofx109.
188. Saab S, Sikavi C, Jimenez M, Viramontes M, Allen R, Challita Y, Mai M, Esmailzadeh
N, Grotts J, Choi G, Durazo F, El-Kabany M, Han SH, Moreno E. Clinical Food
Addiction Is Not Associated with Development of Metabolic Complications in Liver
Transplant Recipients. J Clin Transl Hepatol. 2017;5:335-342.
189. Saab S, Viramontes, MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG,
Saab EG, Saab CM, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M.
Hepatitis C Virus Prevalence in Egyptian-Americans in Southern California. J Clin
Gastroenterol 2018;52:55-59.
190. Nieto J, Khaleel H, Challita Y, Jimenez M, Baron TH, Walters L, Hathaway K, Patel K,
Lankarani A, Herman M, Holloman, D, Saab S. Endoscopic Ultrasound guided Fine
Needle Core Liver Biopsy using a Novel 19 Gauge Needle with Modified One Pass One
Actuation Wet Suction Technique. Gastrointestinal Endoscopy. 2018;87:469-475
191. Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shawkat M, Yousif S, Ullah W, Alabbad S, Al-
Jedai A, Ajlan A, Broering D, Saab S, Al Sebayel M, Al-Hamoudi W. Treatment of
Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in
the Liver Transplant Setting. Transplantation. 2017;101:2739-2745
192. Sikavi C, Chen PH, Lee A, Saab EG, Choi G, Saab S. Hepatitis C and Human
immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No
Longer A Difficult to Treat Population. Hepatology 2018;67:847-857.
193. Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of Cardiovascular Events in
Patients with Primary Biliary Cholangitis ~ Systematic Review. J Clin Transl Hepatol
2018;6:119-126.
194. Corson M, Moch A, Saab S. Hepatitis C Virus Treatment in Patients with Chronic
Kidney Disease and in Kidney Transplant Recipients. Gastroenterol Hepatol (N Y).
2018;14:280-285.
195. Hanna RM, So N, Kaldas M, Hou J, Arman F, Sangalang M, Yanny B, Selamet U, Saab
S, Nobakht N, Rastogi A. Case Report: Patient with Hepatitis C, p-ANCA, and
Cryoglobulin Antibodies Presenting with Necrotizing Crescentic p-ANCA G
lomerulonephritis. Case Rep Nephrol Dial 2018;8:161-170
Saab 46
196. Saab S, Mehta D , Hudgens S, Grunow N, Bao Y , Brett Pinsky. Effect of
ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health related quality of life for
patients with hepatitis C. Liver International 2018;38(8):1377-1394
197. Saab S, Abbey B, Challita Y, Adeniyi A, Aziz A, Choi G, Durazo F, El-Kabany M, Han
SH, Busuttil RW. Impact of Sustained Viral Response with Direct Acting Agents on
Glycemic Control and Renal Function in Liver Transplant Recipients. Experimental Clin
Transplant 2018;16:419-424
198. Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a
Comprehensive Dataset of Hepatitis C Patients and Examination of Disease
Epidemiology in the United States, 2013–2016. Adv Ther 2108;35:1087-1102.
199. Yanny B, Saab S, Durazo F, Latt N, Mitry A, Mikhail MM, Hanna RM, Aziz A, Sahota
A. Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better
Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population
Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL. Dig Dis Sci.
2018;63:3480-3486.
200. Saab S, Saggi SS, Akbar M, Choi G. Presumed Consent: A Potential Tool for Countries
Experiencing an Organ Donation Crisis. Dig Dis Sci. 2018; 64:1346-1355. With
accompanying editorial.
201. Le LB, Rahal HK, Viramontes MR, Meneses KG, Dong TS, Saab S. Patient Satisfaction
and Health Care Utilization using Telemedicine in Liver Transplant Recipients. Dig Dis
Sci. 2018;64:1150-1157.
202. Saab S, Challita. Y, Kahaleh M, Holloman D, Hathaway K, Nieto J. Case Series Review
of the Safety and Efficacy of Endoscopic Ultrasound Guided Splenic Mass Core Biopsy.
Clinical Endoscopy 2018;51:600-601.
203. Saab S, Ahn T, McDaniel T, Yanny B, Tong, M. Economic Comparison of Serologic and
Molecular Screening Strategies for Hepatitis C Virus. Gastroenterol Hepatol (N Y).
2018;14:459-462.
204. Yanny B, Latt N, Saab S, Han S, Choi G, Kramer J, Sahota A. Risk of Hepatitis B Virus
Reactivation Among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus
Infection. J Clin Gastroenterology 2018;52:908-912.
205. Phan J, Ng V, Sheinbaum A, French S, Choi G, El Kabany M, Durazo F, Saab S, Tong
M, Busuttil R, Han SH. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to
Hepatocellular Carcinoma Development Without Cirrhosis. J Clin Gastroenterol.
2018;53:309-313.
206. Lee EW, Saab S, Kaldas F, Fletcher S, Busuttil RW, Durazo F, McWilliams JP,
DiNorcia J 3rd, Padia SA, Kee ST. Coil-Assisted Retrograde Transvenous Obliteration
(CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. Am
J Gastroenterol. 2018;113:1187-1196.
207. Saab S, Kardashian A, Saggi S, Choi G, Agopian A, Tong MJ, Use of Hepatitis C
Positive Grafts in Hepatitis C Negative Liver Transplant Recipients is Cost-Effective.
Clinical Transplantation 2018;32:e13383.
208. Saab S, Le Long, Saggi S, Sundaram V, Tong M. Towards the Elimination of Hepatitis C
in the United States. Hepatology 2018; 67:2449-2459.
209. Saab S, Youssef C, Chen PH, Jimenez MA, Lee AD, Saab EG, Ahn T, Choi G, Durazo
F, El-Kabany M, Han SH, Grotts J, Agopian VG, Busuttil RW. The Elimination of
Hepatitis C in Liver Transplant Recipients. J Clin Transl Hepatol. 2018;28;6:247-250.
210. Reardon LC, DePasquale EC, Tarabay J, Cruz D, Laks H, Biniwale RM, Busuttil RW,
Kaldas FM, Saab S, Venick RS, Lin JP, Nsair A, Deng MC, Ardehali A, Caderias M,
Saab 47
Iygengar A, Aboulhosn JA. Heart and heart-liver transplantation in adults with failing
Fontan physiology. Clin Transplant. 2018;32(8):e13329.
211. Sue MJ, Lee EW, Saab S, McWilliams JP, Durazo F, El-Kabany M, Kaldas F, Busuttil
RW, Kee ST. Transjugular Liver Biopsy: Safe Even in Patients With Severe
Coagulopathies and Multiple Biopsies. Clin Transl Gastroenterol. 2019;10(7):e00063.
212. Aby E, Phan J. Troung E. Grotts J, Saab S. Inadequate Hepatocellular Carcinoma
Screening in patients with Non-Alcoholic Steatohepatitis Cirrhosis. J Clin Gastroenterol
2018;53:142-146.
213. Aby E, Lee E, Saggi SS, Viramntes MR, Grottss JF, Agopian A, Busuttil RW, Saab S
Pre-Transplant Sarcopenia in Patients with NASH Cirrhosis does not impact re-
hospitalization or mortality. J Clin Gastroenterology 2018;53(9):680-685.
214. Saab S, Song D. Challita YP, Zhou TX, Saab EG, Viramontes MR, Choi G, Durazo FA,
Han SB, El Kabany MM, Jackson NJ, Busuttil RW. Long-term Outcomes with Oral
Therapy in Liver Transplant Recipients with Hepatitis B. Clin Transplant 2019 (in press).
215. Benitez TM, Fernando SM, Amini C, Saab S. Geographically Focused Collocated
Hepatitis C Screening and Treatment in Los Angeles’s Skid Row. Dig Dis Sci 2020 (in
press).
216. Fong T, Wu C, Wu S, Saab S. Hepatitis B Surface Antigen Levels Predict Spontaneous
Hepatitis B Surface Antigen Seroconversion in Inactive Hepatitis B Carriers. J Clin
Gastroenterology 2020 (in press).
217. Lee EW, Lee AE, Saab S, Kee ST. Retrograde Transvenous Obliteration (RTO): A New
Treatment Option for Hepatic Encephalopathy. Dig Dis Sci. 2020 (in press)
218. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among
Hospitalized US Adults. JAMA Netw Open. 2020;3(4):e201997
219. Nieto J, Dawod E, Deshmukh A, Penn E, Adler D, Saab S. EUS-Guided Fine Needle
Core Liver Biopsy with a Modified 1-Pass 1-Actuation Wet Suction Technique:
Comparing Two Types of EUS Core Needles. Endoscopy International Open. 2020 (in
press).
220. Hameed B, Veracruz N, Saab S, Wong R. The Association Between Nonalcoholic Fatty
Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extra-Hepatic Cancers. J
Cli Exp Hepatol 2020 (in press).
C. RESEARCH PAPERS - PEER REVIEWED (SUBMITTED) None.
B. RESEARCH PAPERS - PEER REVIEWED (IN PRESS)
RESEARCH PAPERS (NON-PEER REVIEWED) None.
D. RESEARCH PAPERS - NON-PEER REVIEWED None.
E. RESEARCH PAPERS - NON-PEER REVIEWED (IN PRESS) None.
F. RESEARCH PAPERS - NON-PEER REVIEWED (SUBMITTED) None.
Saab 48
BOOK CHAPTERS
1. Saab S, Martin P. Liver and biliary diseases (book review). In: Friedman LS, ed. Print
and media reviews. Gastroenterology 1998;115:505.
2. Saab S, Jutabha R. Approach to the patient with lower gastrointestinal bleeding. In:
Rose BD, ed. UpToDate. Wellesley MA: UpToDate 2000.
3. Saab S, Jutabha R. Etiology of lower gastrointestinal bleeding. In: Rose BD, ed.
UpToDate. Wellesley MA: UpToDate 2000.
4. Saab S, Rojter SE. Cirrhosis. In Encyclopedia of Public Health, ed. L. Breslow. New
York & Detroit: Macmillan Reference USA. 2002. 205-7.
5. Saab S, Han SHB, Martin P. Management of the patient awaiting liver transplantation.
In Practical Manual of Abdominal Organ Transplantation, Manzarbeitia C, ed. Kluwer
Academic/Plenum Publishers. 2002: 27-40.
6. Saab S, Jutabha R. Endoscopic management of lower GI bleeding. In: Wong RCK, Van
Dam J, eds. Handbook of Gastrointestinal Endoscopy. Austin: RG Landes Co: 2004.
7. Saab S, Rosen H. Approach to the Patient with Chronic Hepatitis B and C. In: Atlas of
Gastroenterology. Yamada T, Albers DH, Kaplowitz N, Owyang C, Powell DW, Kalloo
A, eds. Blackwell Publishers 2008.
8. Chang M, Sung H, Saab S. Treating HCV after Liver Transplantation. In Chronic
Hepatitis C Virus: Lessons from the Past Promise for the Future, ed Shiffman ML. New
York: Publisher Springer Science. 2011.
9. Suraweera D, Konyn P, Vu T, Saab S. Epidemiology of Chronic Liver Disease:
Hepatocellular Carcinoma. In Clinical Epidemiology of Chronic Liver Disease. eds: Gish
R and Wong R. Cambridge: Springer. 2018
10. Corson M, Najarian L, Saab S. Management of Ascites. In: Liver Disease: A Clinical
Casebook. eds: Cohen SM and Davitkov P. New York: Publisher Springer Science. 2019.
LETTERS TO THE EDITOR None.
REVIEWS
1. Yao F, Saab S. A practical approach to abnormal liver chemistries. Practical
Gastroenterol 1997;21:11-17.
2. Saab S, Martin P. Hepatitis C: a practical approach to diagnosis and management.
Family Practice Recertification 1998;20:21-44.
3. Saab S, Martin P. Medical care of the liver transplant patient (book review). In: Maher
J, ed. Hepatology elsewhere. Hepatology 1998; 27:1449.
4. Saab S, Martin P. The role of consensus interferon for chronic hepatitis C infection.
Current Treatment Options Infect Dis 2000;2:115-9.
5. Saab S, Han SHB, Martin P. Liver transplantation: selection, listing criteria, and pre-
operative management Clin Liv Dis 2000;4:513-532.
6. Han SHB, Saab S, Martin P. Acute viral hepatitis. Curr Treat Options Gastroenterol.
2000;3:481-486.
7. Saab S, Martin P. Update on hepatitis C. Medscape Gastroenterol, 3(1) 2001.
8. Lin R, Saab S. The current status of hepatitis C virus infection. Inter J Art Organs.
2001;24: 838-42.
9. Saab S, Wang V. Recurrent hepatitis C in liver transplant recipients: diagnosis, natural
history and therapeutic options. J Clin Gastroenterol 2003;37:155-163.
10. Chang A, Dixit V, Saab S. Fulminant hepatic failure. Curr Treat Options
Gastroenterol. Curr Treat Options Gastroenterol. 2003;6:473-479
Saab 49
11. Saab S, Busuttil RW. Practical management of hepatitis C in liver transplant recipients.
Minerva Chirurgica 2003;58:479-89.
12. Karson H, Rojter SE, Saab S. Cirrhosis: a preventable medical and public health
concern. Postgrad Med 2004;115:25-30.
13. Wang V, Saab S. Liver transplantation in the era of MELD. Liver International
2004;24:1-8.
14. Kim A, Saab S. Treatment of hepatitis C. Am J Med. 2005;118:808-15.
15. Nieto J, Saab S. Outcomes of liver transplantation using hepatitis B core positive live
grafts: implications for prophylaxis. Current Hepatitis Reports 2006;5:33-39.
16. Dong M, Saab S. Management of Cirrhosis. Disease a Month 2008;54:445-56.
17. Surti B, Chi A, Saab S. Update on Management of Hepatitis B before and after Liver
Transplantation. Current Hepatitis Reports 2008;7:25-32.
18. Nieto J, Saab S. Outcomes of liver transplantation using hepatitis B core positive live grafts:
implications for prophylaxis. 2008 Update. Current Hepatitis Reports 2008;2:268-75.
19. Surti B, Tan J, Saab S. Pregnancy in Liver Transplantation. Liver International 2008;
28:1200-6.
20. Tan J, Surti B, Saab S. Cirrhosis and Pregnancy. Liver Transpl 2008;14:1081-91.
21. Tan J, Saab S. Hepatitis B: Indications for therapy indication. Medscape Gastroenterol, 3
2008.
22. Hunt DR, Saab S. Viral hepatitis in incarcerated adults: a medical and public health concern.
Am J Gastroenterol. 2009;104:1024-31.
23. Landaverde C, Saab S. Optimizing Peg-Interferon and Ribavirin Dosing in Difficult to Treat
Patient Populations. Current Hepatitis Reports 2009, 8:43–51
24. Saab S. Academic Perspectives on Hepatitis C: Treatment Adherence Gastroenterology and
Hepatology 2009. Mar: 5 (3).
25. Dong M, Saab S. Management of Cirrhosis. Gastroenterology and Hepatology
2009;5:191-197.
26. Tan J, Saab S. New Strategies in Hepatitis B Treatment. Medscape Gastroenterol, 2009.
27. Martyak LA, Yeganeh M, Saab S. Hepatitis C and Lymphoproliferative Disorders: From
Mixed Cryoglobulinemia to Non-Hodgkin’s Lymphoma. Clinical Gastroenterology and
Hepatology 2009 2009;7:900-5.
28. Siqueira F, Kelly T, Saab S. Refractory Ascites: Pathogenesis, Clinical Impact and
Management. Gastroenterology and Hepatology 2009;5:1-10.
29. Bownik H, Saab S. Health-Related Quality of Life after Liver Transplantation for Adult
Recipients. Liv Transplant 2009;15:S42-9.
30. Chak E, Saab S. Pegylated Interferon and Ribavirin Dosing Strategies to Enhance
Sustained Virologic Response. Curr Hepat Rep. 2010;9:147-154.
31. Bownik H, Saab S. The Effects of Hepatitis C Recurrence on Health Related Quality of
Life in Liver Transplant Recipients. Liver International. 2010;30:19-30.
32. Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic
Response. Current Hepatitis Reports 2010.9:147-154
33. Movahedi Z, Holt CD, Saab S. Immunosuppression Strategies in Liver Transplantation: A
Primer. Exp Clin Transplant 2010;8:83-90.
34. Desai S, Hong J, Saab S. Cardiovascular Risk Factors Following Orthotopic Liver
Transplantation: Predisposing Factors, Incidence, and Management. Liver International 2010;
30:948-57.
35. Chak E, Saab S. Risk Factors and Incidence of De Novo Malignant in Liver Transplant
Recipients. A Systematic Review. Liver International 2010;30:1247-58.
Saab 50
36. Ng V, Saab S. Clinical Focus -- Management of Hepatitis C in Special Populations:
Understanding and Applying the Evidence. Medscape Gastroenterol (in press).
37. El-Masry M, Puig C, Saab S. Recurrence of Non-Viral Liver Disease after Orthotopic Liver
Transplantation. Liver International 2011;31:291-302.
38. Ng Vivian, Saab S. Effects of a Sustained Viral Response on Outcomes of Patients with
Chronic Hepatitis C. Clin Gastroenterol Hepatol 2011;9:923-30.
39. Khungar V, Saab S. Cirrhosis with Refractory Ascites: Serial Large Volume Paracentesis,
TIPS, or Transplantation? Clin Gastroenterol Hepatol. 2011;931-5.
40. Change M, Saab S. Interferon for Hepatitis B: Which Populations Benefit the Most. Curr
Hepatitis Rep 2011 10:285–291
41. Padua D, Bau S, Saab S. Treating Chronic Hepatitis C Viral Infection: Rethinking Dose
Reduction Strategies for PEG-IFN and Ribavirin in the Setting of New Direct Acting Agents.
Current Hepatitis Reports 2013; Published Online.
42. Yu C, Sharma N, Saab S. Hyponatremia: Clinical Associations, Prognosis and Treatment in
Cirrhosis. Exp Clinl Transplant 2013;11:3-11.
43. Saab S. Hepatitis C in Liver Transplantation. Ann Saudi Med. 2013;33:91-93 (supplement).
44. Saab S, Heber D. Nutrition and Liver Disease in Handbook of Nutrition and Food, Third
Edition-Chapter 51. 2013.
45. Manne V, Saab S. Impact of nutrition and obesity on chronic liver disease. Clin Liver Dis.
2014;18:205-18.
46. Saab S. Hepatic Decompensation. Gastronterology and Hepatology 2007.
47. Landaverde C, Saab S. Evaluation of the potential liver transplant recipient. Liver
International 2008;28:1186-9.
48. Sood A, Castrejón M, Saab S. The Approach to the Patient with HIV and Nodular
Regenerative Hyperplasia W J Hepatol 2014;6:55-63.
49. Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A,
Kugelmas M, Gordon SC. The Impact of Hepatitis C Burden: An Evidence Based
Approach. Alimentary Pharmacol Therap 2014;39:518-31.
50. Manne V, Sassi K, Allen R, Saab S. Hepatitis C and Work Impairment: A review of
current literature. J Clin Gastroenterol 2014;48:595-9.
51. Klintmalm GB, Saab S, Hong JC, Nashan B. The Role of Mammalian Target of
Rapamycin Inhibitors in the Management of Posttransplant Malignancy. Clin
Transplant. 2014;28:635-48.
52. Manne V, Allen RM, Saab S. Strategies for the prevention of recurrent hepatitis B virus
infection after liver transplantation. Gastroenterol Hepatol (N Y). 2014;10:175-9.
53. Manne V, Akhtar E, Saab S. Cirrhosis Regression in Patients with Viral Hepatitis B and
C: A Systematic Review. J Clin Gastroenterol. 2014 Oct;48(9):e76-84.
54. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African-Americans. Am J
Gastroenterol. 2014;109:1576-84
55. Wu T, Morgan TR, Klein AS, Volk ML, Saab S, Sundaram V. Controversies in early
liver transplantation for severe alcoholic hepatitis. Annals of Hepatology 2018;17:759-
768.
56. Yanny B, Konyn P, Najarian LM, Mitry A, Saab S. Management Approaches to
Hepatitis B Virus Vaccination Nonresponse. Gastroenterol Hepatol (N Y). 2019;15:93-
99.
57. Wu T, Konyn PG, Cattaneo AW, Saab S. The New Face of Hepatitis C. Dig Dis Sci.
2019 ;64:1782-1788.
Saab 51
58. Saab S, Brown RW. Management of Thrombocytopenia in Patients with Chronic Liver
Disease. Dig Dis Sci. 2019;64:2757-2768
59. Sikavi C, Najarian L, Saab S. Similar Sustained Virologic Response in Real-World and
Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Co-Infection. Dig
Dis Sci 2018;63:2829-2839
60. Shetty A, Buch A, Saab S. Use of Hepatitis C Positive Liver Dig Dis Sci. 2018;64:1110-
1118
61. Frenette C, Isaacson A, Bargellini I, Saab S, Singal G. A Practical Guideline for
Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Inn Qual Out
2019 ;3:302-310.
62. Yanny B, Winters A, Boutros S, Saab S. Hepatic Encephalopathy Challenges, Burden,
and Diagnostic and Therapeutic Approach. Clin Liver Dis. 2019;23:607-623.
63. Aby ES, Saab S. Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. Clin Liver
Dis. 2019;23:589-605.
64. Saab S, Kullar R, Amini C, Grounder P. The Next Frontier: Universal HCV Screening in
pregnant women. American Journal of Obstetrics & Gynecology 2020 (in press).
65. Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for
Thrombocytopenia in Patients with Chronic Liver Disease Undergoing a Scheduled
Procedure. J Clin Gastroenterol 2020 (in press).
66. Yanny B, Boutros S, Saleh F, Saab S. Liver Transplantation for Alcoholic Hepatitis:
Update. Current Opinion in Gastroenterology. 2020 (in press).
67. Saab S, Kullar R, Khalil H, Gounder P. Cost-Effectiveness of Universal Hepatitis C
Screening in Pregnant Women: A Systematic Review. J Clin Gastroenterol 2020 (in
press).
Saab 52
EDITORIALS
1. Saab S. Transmission of hepatitis (invited commentary). In: Rickman LS, Jackson M,
eds. Reviews and comments at a glance. AJIC 1996;24:472-473.
2. Saab S. Historical perspective on pulmonary tuberculosis (invited commentary). In:
Rickman LS, Jackson M, eds. Reviews and comments at a glance. AJIC 1997;25:65-66.
3. Saab S, Yee HF Jr. Hepatorenal syndrome: a treatable process? Adv Gastroenterol
Hepatol Clin Nutr 1998;3:208-213.
4. Saab S, Martin P. Hemolytic anemia and the treatment of chronic hepatitis C (invited
commentary). J Clin Gastroenterol 1999;28:289-290.
5. Saab S, Han SHB. Successful orthotopic liver transplantation (correspondence).
Gastroenterol 2001;120:1561-1562.
6. Saab S. Hepatitis C transmission in the hemodialysis community (invited commentary).
Am J Kid Dis 2001;37:1052-1055.
7. Wang V, Saab S. Ammonia levels and severity of hepatic encephalopathy (invited
editorial). Am J Med 2003;114:237-238.
8. Saab S. Hepatocellular carcinoma screening using alpha-fetoprotein (invited
commentary). J Evidence Based Healthcare 2004;8:221-3.
9. Saab S. Role of High ALT in the Natural History of HBeAg-Negative, HBsAg-Positive
Disease. Clinical Care Options 2009.
10. Padua D, Saab S. Cart before the Horse. Ann Intern Med 2012.
http://www.annals.org/content/156/4/279.short/reply
11. Ng V, Saab S. Can Daily Coffee Consumption Reduce Liver Disease Related Mortality?
Clin Gastroenterol Hepatol. 2013;11:1422-3.
12. Suraweera D, Saab S. Hepatitis C treatment threshold in patients with decompensated
liver disease. Hepatology. 2017;65:1789-1791.
13. Saab S. Current Treatment of Thrombocytopenia in Chronic Liver Disease.
Gastroenterology and Hepatology. 2019;15:558-561.
14. Saab S. Portal Hypertension. Clin Liver Dis. 2019 Nov;23(4):xiii-xiv. doi:
10.1016/j.cld.2019.08.001.
15. Saab S, Kullar R, Gounder P. The Need for Hepatitis C Screening in Pregnant Women.
Obstetrics & Gynecology. 2020 (in press).
16. Saab S, Kim NG, Lee EW. Practical Tips on TIPS: When to Request and When Not to
Request It. Am J Gastroenterol 2020 (in press).
EDITORIALS (IN PRESS) None
PAPERS IN PREPARATION (RESEARCH COMPLETED) None.
ABSTRACTS
POSTER PRESENTATIONS
1. Saab S, Ly D, Lin R, Rojter SE, Han S, Ghobrial RM, Busuttil RW. Cost-effectiveness
of treating hepatitis C after liver transplantation. American Association for the Study of
Liver Diseases annual meeting November 2001, Dallas, TX.
Saab 53
2. Saab S, Chang A, Comulada S, Geeverghese SK, Kunder G, Durazo F, Han, S, Kunder
G, Durazo F, Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil RW. Outcomes
of hepatitis C and hepatitis B core antibody positive grafts in orthotopic liver
transplantation. American Transplant Congress annual meeting May 2003, Washington
DC.
3. Saab S, Wang V, Ibrahim AB, Morrisey M, Durazo F, Han S, Kunder G, Durazo F,
Yersiz H, Ghobrial RM, Farmer DG, Goldstein LI, Busuttil RW. MELD score as a
predictor of post-orthotopic liver transplantation one-year patient and graft survival.
Digestive Diseases Week annual meeting May 2003, Orlando, FL.
4. Ghobrial RM, Carmody IC, Ruiz R, Kelly BS, Farmer DG, Yersiz H, Lipshutz GS, Saab
S, Hiatt J, Busuttil RW. Post-transplantation hepatitis C recurrence is influenced by non-
viral transplant-related factors: 10 years analysis in over 300 patients. American Society
of Transplantation and the American Society of Transplant Surgeons annual meeting.
May 2005, Seattle, WA.
5. Biggins S, Kim WR, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W,
Wiesner R, Kamath P, Terrault N. MELDS: Incorporation of the serum sodium
concentration into MELD: An evidence-based proposal. American Society of
Transplantation and the American Society of Transplant Surgeons annual meeting. May
2005, Seattle, WA.
6. Terrault N, Shiffman M, Lok A, Saab S, Gillespie B, Seeff LB, and the A2ALL Study
Group. Transplant center experience explains differences in the risk of graft failure
between hepatitis C (HCV)-infected reciepients of living donor (LDLT) and deceased
donor (DDLT) liver transplant recipients. American Association for the Study of Liver
Disease Annual Meeting. November 2005, San Francisco, CA.
7. Saab S, Hernandez JC, Chi AC, Tong. Spontaneous Bacterial Peritonitis Prophylaxis
Improves Morbidity and Mortality: A Meta-Analysis. Digestive Diseases Week annual
meeting May 2008, San Diego, CA.
8. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, Farmer DG, Goldstein LI,
Tong MJ, Busuttil RW. Recurrence of Hepatocellular Carcinoma and Hepatitis B
Reinfection in HBsAg Positive Patients after Liver Transplantation. ILTS, July 2008
New York, NY.
9. Everson G, Terrault N, Lok AS, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM,
Kulik LM, Gillespie BW, Everhart JE. Interim analysis of a controlled trial of pre-
transplant peginteferon alfa-2B/ribavirin (PEG/RBV) to prevent recurrent hepatitis C
virus (HCV) infection after liver transplantation (LT) in the adult-to-adult liver
transplantation (A2ALL) study. American Association for the Study of Liver Disease
Annual Meeting. November 2009, Boston, MA.
10. Levitsky J,. Norvell J, Watt KD, Curry MP, Tewani SK, McCashland TM, Shaked A,
Hoteit MA, Chi AC, Saab S, Tien A, Fiel MD, Schiano TD. Immunological Graft
Dysfunction Occurring During Pegylated Interferon Therapy for Recurrent Hepatitis C
Post Liver Transplantation.
11. McCombs J, Matsuda T, Tonhu-Mihara I, Saab S, Hines P, L’Italian G, Juday T, Yuan
Y. Impact of Treatment on Long-Term Morbidity and Mortality in Chronic Hepatitis C
Patients Receiving Care Through the U.S. Veterans Health Administration. American
Association for the Study of Liver Diseases annual meeting November 2013,
Washington, DC.
12. Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile Infection in
Patients with Alcoholic Hepatitis. EASL April 2014, London, Great Britain.
Saab 54
13. Saab S, Gordon SC, Park H, Ahmed A, Younossi ZM. A Decision Analytic Markov
Model to Evaluate the Health Outcomes for Sofosbuvir for Previously Untreated Patients
and Those Without Treatment Options with Chronic Hepatitis C Virus. Plenary Session.
Digestive Diseases Week annual meeting May 2014, Chicago, IL.
14. Saab S, Gordon SC, Park H, Ahmed A, Younossi ZM. A decision analytic Markov
model to evaluate the health outcomes of sofosbuvir for previously untreated patients and
those without treatment options with chronic hepatitis c virus. AASLD Plenary Session I.
Digestive Diseases Week. May 2014. Chicago, IL.
15. Agarwa K, Gane E, Forns X, Mann M, Saab S, Colombo M, Younossi, Terrault N. The
cost-effectiveness of sofosbuvir treatment pre-transplant to prevent HCV recurrence post-
transplant. ILTS June 2014, London, Great Britain.
16. Yanny B, Konyn P, Najarian L, Mitry A, Mikhail M, Saab S. Approaches to Hepatitis B
Vaccination Nonresponse. American Association for the Study of Liver Diseases Annual
Meeting. November 2018. San Francisco, CA 2018. Abstract 216.
POSTER PRESENTATIONS
1. Saab S, Martin P, Han S, Ghobrial RM, Markmann JF, Farmer DG, Drazan K, Seu P,
Goss JA, Busuttil RW. Coinfection of hepatitis B and C increases the risk of developing
hepatocellular carcinoma. American Association for the Study of Liver Diseases annual
meeting November 1998, Chicago, IL.
2. Bedford R, Saab S, Soliman GY, Han S, Ghobrial RM, Farmer DG, Martin P, Busuttil
RW. Nasobiliary drainage is the treatment of choice for biliary leakage following
orthotopic liver transplantation. American Gastroenterology Association annual meeting
May 1999, Orlando, FL.
3. Saab S, Soliman GY, Han SH, Martin P. Female patients over 50 years of age are at
increased risk of developing hepatocellular carcinoma with cirrhosis due to HCV.
American Gastroenterology Association annual meeting May 1999, Orlando, FL.
4. Saab S, Soliman GY, Han SH, Martin P. Hepatitis A seroprevelance in patients with
cirrhosis due to hepatitis C. American Association for the Study of Liver Diseases annual
meeting November 1999, Dallas, TX.
5. Saab S, Langfield D, Gitnick G, Yee HF Jr. Hepatitis C prevalence and incidence in
dialysis patients. American Association for the Study of Liver Diseases annual meeting
November 1999, Dallas, TX.
6. Saab S, Soliman GY, Han SH, Martin P, Ghobrial RM, Farmer D, Busuttil RW, Lassman
CR. Alpha-1 antitrypsin deficiency is an under-recognized cause of decompensated liver
disease in patients undergoing orthotopic liver transplantation. American Association for
the study of Liver Diseases annual meeting November 1999, Dallas, TX.
7. Saab S, Thigman M, Yee HF Jr. Endothelin-1 mediates stellate cell contractility through
the endothelin-A receptor. American Association for the Study of Liver Diseases annual
meeting November 1999, Dallas, TX.
8. Saab S, Martin P, Yee HF Jr. Serology testing prior to hepatitis A vaccination in high
risk groups. American Association for the Study of Liver Diseases annual meeting
November 1999, Dallas, TX.
9. Saab S, Hurwitz EL, Soliman GY, Han SH, Martin P, Farmer DG, Ghobrial RM,
Busuttil RW. Asian patients and patients over 50 years of age are at increased risk of
developing hepatocellular carcinoma with cirrhosis due to hepatitis C. American
Association for the Study of Liver Diseases annual meeting November 1999, Dallas, TX.
Saab 55
10. Saab S, Martin P, Ly D, Langfield D, Brezina M ,Gitnick G, Yee HF Jr. Viral hepatitis
is an infrequent cause of elevated alanine aminotransferase levels in hemodialysis
patients. American Gastroenterology Association annual meeting May 2000, San Diego,
CA.
11. Saab S, Martin P, Ly D, Langfield D, Brezina M, Gitnick G, Yee HF Jr. De novo
hepatitis B and C infection s can occur in the absence of alanine aminotransferase
elevations in dialysis patients. American Gastroenterology Association annual meeting
May 2000, San Diego, CA.
12. Saab S, Martin P, Ly D, Brezina M, Gitnick G, Yee HF Jr. Hepatitis C antibody based
testing is the preferred strategy for hepatitis C screening in hemodialysis patients.
American Association for the Study of Liver Diseases annual meeting October 2000,
Dallas, TX.
13. Ly D, Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Hepatitis B immunization
causes detectable hepatitis B surface antigen in hemodialysis patients. American
Association for the Study of Liver Diseases annual meeting October 2000, Dallas, TX.
14. Shimoda M, Saab S, Soliman GY, Han S, Ghobrial RM, Farmer DG, Bedford RA,
Goldstein LI, Martin P, Busuttil RW. A cost analysis of biliary anastomosis with or
without T-tube after orthotopic liver transplantation. American Association for the Study
of Liver Diseases annual meeting October 2000, Dallas, TX.
15. Weston S, Saab S, Ly D, Brezina M, Yee HF Jr, Gitnick G, Han S. A cost-effective
decision analysis model comparing two strategies for hepatitis B immunity in the
hemodialysis community. American Gastroenterology Association annual meeting May
2001, Atlanta, GA.
16. Ghobrial RM, Farmer DG, Stedman R, Yersiz H, Lassman C, Danino N, Collisson E,
Han S, Saab S, Busuttil RW. Adverse effects of HCV recurrence in over five hundred
liver transplantations. The American Society of Transplantation and the American
Society of Transplant Surgeons annual meeting May 2001, Chicago, IL.
17. Shimoda M, Saab S, Morrisey M, Ghobrial MR, Farmer DG, Han S, Bedford RA,
Goldstein LI, Martin P, Busuttil RW. A cost-effectiveness analysis of biliary
anastomosis with or without t-tube after orthotopic liver transplantation. The American
Society of Transplantation and the American Society of Transplant Surgeons annual
meeting May 2001, Chicago, IL.
18. Ghobrial RM, Amersi F, Farmer DG, Chen P, Anselmo DM, Baquerizo A, Geeverghese
S, Hisitake G, Renz J, Han S, Saab S, Busuttil RW. Rapid and severe early HCV
recurrence following adult living donor liver transplantation. The American Society of
Transplantation and the American Society of Transplant Surgeons annual meeting April
2002, Washington, DC.
19. Ghobrial RM, Gornbein J, Anselmo D, Steadman R, Danino N, Yersiz H, Saab S,
Busuttil RW. Pretransplantation model to predict posttransplant survival in OLT for
HCV. The American Society of Transplantation and the American Society of Transplant
Surgeons annual meeting April 2002, Washington, DC.
20. Saab S, Ghobrial RM, Han S, Chen P, Farmer D, Danino N, Yersiz H, Goldstein LI,
Bususttil RW. Hepatitis C infected grafts may be used in orthotopic liver transplantation:
A matched analysis. The American Society of Transplantation and the American Society
of Transplant Surgeons annual meeting April 2002, Washington, DC.
21. Derosa V, Nieto J, Saab S. Decision anayltic model comparing strategies for primary
prophylaxis of variceal bleeding in patients with hepatic cirrhosis. American
Gastroenterology Association annual meeting May 2002, San Francisco, CA.
Saab 56
22. Kanwal F, Chen D, Saab S, Durazo F, Busuttil RW, Han S. Predictors of poet-liver
transplant altered metal status of unclear etiology. American Association for the Study of
Liver Diseases annual meeting November 2002, Boston, MA.
23. Vogel W, Ferenci P, Fontana R, Arbor A, Saab S, LaBrecque D, Pappas SC, Sidhu RK,
Harb GE. Peginterferon alfa-2A (40KD) (Pegasys ®) in liver transplant recipients with
established recurrent hepatitis C; interim results of an ongoing randomized multicenter
trial. American Association for the Study of Liver Diseases annual meeting November
2002, Boston, MA.
24. Saab S, DeRosa VP, Nieto J, Durazo F, Han S, Roth B. Costs and clinical outcomes of
primary prophylaxis of variceal bleeding in cirrhotics: A decision analytic model.
American Association for the Study of Liver Diseases annual meeting November 2002,
Boston, MA.
25. Nieto J, Saab S. Medical versus surgical and radiological treatment of refractory ascites:
A meta-analysis of randomized controlled trials. American Association for the Study of
Liver Diseases annual meeting November 2002, Boston, MA.
26. Karsan HA, Lee C, Dong PR, Durazo F, Saab S, Han S. Do transjugular intrahepatic
postosystemic shuts (TIPS) for refractory ascites really work? American Association for
the Study of Liver Diseases annual meeting November 2002, Boston, MA.
27. Saab S, Hu RR, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H,
Ghobrial R, Farmer DG, Busuttil RW, Lassman C. Discordance between alanine
aminotransferase and liver histology in liver transplant recipients treated with ribivarin
monotherapy for recurrent hepatitis C virus. American Association for the Study of Liver
Diseases annual meeting November 2002, Boston, MA.
28. Saab S, Ghobrial RM, Ibrahim AB, Han S, Chen P, Farmer D, Durazo F, Yersiz H,
Goldstein LI, Busuttil RW. Hepatitis C positive grafts may be used in orthotopic liver
transplantation: A matched analysis. American Association for the Study of Liver
Diseases annual meeting November 2002, Boston, MA.
29. Saab S, Ly D, Nieto J, Kanwal F, Durazo F, Han S, Busuttil. Hepatocellular carcinoma
surveillance in patients awaiting liver transplantation can be cost-effective. American
Association for the Study of Liver Diseases annual meeting November 2002, Boston,
MA.
30. Saab S, Wang VS, Ibrahim AB, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H,
Morrisey M, Godstein LI, Busuttil RW. MELD score can predict post-orthotopic liver
transplantation one-year patient and graft survival. American Gastroenterology
Association annual meeting May 2003, Orlando, FL.
31. Saab S, Wang V, Ibrahim AB, Durazo F. Han S, Farmer DG, Ghobrial RM, Yersiz H,
Goldstein LI, Busuttil RW. MELD score can predict port-orthotopic liver transplantation
one-year patient and graft survival. The American Society of Transplantation and the
American Society of Transplant Surgeons annual meeting May 2003, Washington, DC.
32. Saab S, Chang A, Comulada S, Geeverghese SK, Anselmo DM, Ghobrial RM, Kunder
G, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Busuttil RW. Outcomes of
hepatitis C and hepatitis B core antibody positive grafts in orthotopic liver
transplantation. The American Society of Transplantation and the American Society of
Transplant Surgeons annual meeting May 2003, Washington, DC.
33. Ghobrial RM, Fondevila C, Limanond P, Raman SS, Lassman C, Sayre J, Saab S, Lu D,
Busuttil RW. Utility of liver biopsy and computed tomography in evaluation of
candidates for living donor liver transplantation. The American Society of
Saab 57
Transplantation and the American Society of Transplant Surgeons annual meeting May
2003, Washington, DC.
34. Ghobrial RM, Huang Y, Farmer DG, Carmody IC, Gornbein J, Steadman R, Saab S,
Goldstein L, Yersiz H, Durazo F, Han S, Tang L, Busuttil RW. Posttransplant hepatitis C
recurrence is influenced by non-viral transplant related factors: Ten-year analysis in over
300 patients. The American Society of Transplantation and the American Society of
Transplant Surgeons annual meeting May 2003, Washington, DC.
35. Tsuchiya M, Saab S, Farmer DG, Saggi B, Gordon, SA, Hisatake GM, Lenz JF, Ghobrial
MR, Yersis H, Busuttil RW. Liver transplantation for obesity related cryptogenic
cirrhosis. How does weight affect post-operative survival? American Association for the
Study of Liver Diseases annual meeting October 2003, Boston, MA.
36. Ghobrial RM, Carmody I, Huang YM, Saab S, Gornbein JA, Steadman R, Han S,
Durazo Farmer DG, Yersiz H, Holt CD, Goldstein L, Busuttil RW. Early hepatitis C
recurrence following liver transplantation is influenced by operative and per-transplant
variables. American Association for the Study of Liver Diseases annual meeting October
2003, Boston, MA.
37. Kamal M, Lassman CR, Ghobrial RM, Saab S, Marks K, Busuttil RW. Histologic
findings in potential living liver donor biopsies. American Association for the Study of
Liver Diseases annual meeting October 2003, Boston, MA.
38. Nieto J, Saab S. Transjugular intrahepatic portosystemic shunt versus paracentesis in the
treatment of refractory ascites: A meta-analysis of randomized trials. American
Gastroenterology Association annual meeting May 2004, New Orleans, LA.
39. Fondevila C, Ghobrial RM, Bombuy E, Gordon S, Fuster J, Saggi B, Charco R, Saab S,
Busuttil RW. Definition of donor surgical variants associated with reduced graft
outcomes following ALDLT. The American Society of Transplantation and the
American Society of Transplant Surgeons annual meeting May 2004, Boston, MA.
40. Saab S, Niho H, Comulada S, Ghobrial RM, Hiatt J, Durazo F, Han S, Farmer DG, Holt
C, Yersiz H, Goldstein LI, Busuttil RW. Risk factors for death in recipients with
recurrent hepatitis C cirrhosis. The American Society of Transplantation and the
American Society of Transplant Surgeons annual meeting May 2004, Boston, MA.
41. Ghobrial RM, Holt CD, Sievers TM, Saab S, Artinian L, McDiarmid SV, Busuttil RW.
Mycophenolate mofetil in liver transplantation for hepatitis C: Effect on recurrence and
pharmacokinetics. The American Society of Transplantation and the American Society
of Transplant Surgeons annual meeting May 2005, Seattle, WA.
42. Ghobrial RM, Holt CD, Sievers TM, Saab S, Artinian L, McDiarmid SV, Busuttil RW.
Mycophenolate mofetil: Pharmacokinetics and effect on hepatitis C recurrence n liver
transplantation. The American Society of Transplantation and the American Society of
Transplant Surgeons annual meeting May 2005, Seattle, WA.
43. Saab S, Ibrahim AB, Shpaner A, Brito I, Fraser K, Marehbian J, Durazo F, Han S,
Farmer DG, Ghobrial RM, Holt C, Yersiz H, Goldstein LI, Tong MJ, Busuttil RW.
Prevalence and risk factors for diabetes mellitus in liver transplantation recipients. The
American Society of Transplantation and the American Society of Transplant Surgeons
annual meeting May 2005, Seattle, WA.
44. Saab S, Landaverde C, Ibrahim A, Durazo F, Han S, Farmer DG, Ghobrial M, Holt C,
Yersiz H, Goldstein L, Lipshutz G, Tong MJ, Busuttil RW. Predictors of mortality and
MELD scores changes while waiting for liver transplantation. The American Society of
Transplantation and the American Society of Transplant Surgeons annual meeting May
Saab 58
2004, Boston, MA. The American Society of Transplantation and the American Society
of Transplant Surgeons annual meeting. May 2005, Seattle, WA.
45. Saab S, Nguyen S, Ibrahim A, Tong M. Management of Cirrhosis in Southern
California. American Gastroenterology Association annual meeting May 2005.
46. Kim A, Bouajram R, Dorn A, Saab S. The treatment of chronic hepatitis C in HIV-
infected patients: a meta-analysis. American Gastroenterology Association annual
meeting May 2006.
47. Trotter JF, Blei AT, Everhart JE, Lok AS, Wisniewski KA, Freise CE, Saab S, Campsen
PJ, Study Group and the A2ALL. Outcomes of Donors and Recipients Following Living
Donor Liver Transplantation for Acute Liver Failure. American Association for the Study
of Liver Diseases annual meeting October 2006, Boston, MA.
48. Saab S, Wiese C, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,
Goldstein LI, Tong MJ, Busuttil RW. Employment and quality of life in liver transplant
recipients. American Association for the Study of Liver Diseases annual meeting
October 2006, Boston, MA.
49. Martyak LA, Taqavi E, Saab S. Lamivudine Prophylaxis for Hepatitis B Reactivation in
Patients Undergoing Cytotoxic Chemotherapy: A Systematic Review. American
Gastroenterology Association annual meeting May 2007.
50. Saab S, Dong M, Joseph T, Tong M. Hepatitis B prophylaxis in patients undergoing
chemotherapy for lymphoma: A decision analysis model. American Gastroenterology
Association annual meeting May 2007.
51. Saab S, Ibrahim AB, Surti B, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM,
Goldstein LI, Tong MJ, Busuttil RW Pre-transplant variables associated with qualify of
life in liver transplant recipients. American Association for the Study of Liver Diseases
annual meeting October 2007, Boston, MA.
52. Tan J, Joseph T, Saab S. Treating Hepatitis C in the Prison Population is Cost-Saving.
American Gastroenterology Association annual meeting May 2008, San Diego, CA.
53. Bownik H, Saab S. Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndrome:
An Example Of Sequential Development. Presented at the SGIM National Meeting. May
2009, Miami, Florida. Winner of Outstanding Clinical Vignette.
54. Saab S, Hunt D, Stone MA, McClune A, Tong MJ. Timing of Hepatitis C Antiviral
Therapy Pre and Post Liver Transplantation: A Decision Analysis Model. American
Association for the Study of Liver Diseases annual meeting October 2009, Boston, MA.
55. Saab S, McTigue M, Finn R, Busuttil RW. Sorafenib Prophylaxis is Effective in
Preventing Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.
International Liver Transplantation Society annual meeting. June 2010, Hong Kong,
China
56. McCombs J, Yuan Y, Shin J, Saab S. Chronic Hepatitis C Infections and the Risk of
Depression and Other Adverse Events. American Association for the Study of Liver
Diseases annual meeting October 2010, Boston, MA
57. McCombs J, Yuan Y, Yu Y, Saab S. A longitudinal database study of economic
consequences of chronic hepatitis C virus (HCV) infections in U.S. ISPOR 16th Annual
International Meeting May 2011, Baltimore, MD.
58. McCombs J, Yuan Y, Yu Y, Saab S. Real-World Evaluation of the Economic Impact of
Duration of Drug Therapy in the Treatment of Hepatitis C Virus (HCV). American
Gastroenterology Association annual meeting May 2011, Chicago, IL. CA.
Saab 59
59. McCombs J, Yuan Y, Yu Y, Saab S. Impact of Newly Diagnosed Hepatitis C Infections
on Health care Costs American Gastroenterology Association annual meeting May 2011,
Chicago, IL. CA. (Poster of Distinction)
60. Younossi ZM, Gordon SC, Saab S, Ahmed A, Brogan A, Cure S. A Decision Analytic
Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated
Patients with Chronic Hepatitis C Virus Genotype 1 Infection. American Association for
the Study of Liver Diseases annual meeting November 2013, Washington, DC.
61. Younossi ZM, Saab S, Gordon SC, Ahmed A, Brogan A, Guerra I. Evaluation of the
Long-Term Health Outcomes Associated with Earlier Versus Later Initiation of
Treatment in Previously Untreated Patients with Chronic Hepatitis C Virus Genotype 1
Infection. American Association for the Study of Liver Diseases annual meeting
November 2013, Washington, DC.
62. McCombs J, Matsuda T, Tonhu-Mihara I, Saab S, Hines P, L’Italian G, Juday T, Yuan
Y. Using Laboratory Data to Predict Long-Term Morbidity and Mortality in Chronic
Hepatitis C Patients in the U.S. Veterans Health Administration. American Association
for the Study of Liver Diseases annual meeting November 2013, Washington, DC.
(Poster of Distinction)
63. Saab S, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M,
Han S, Busuttil RW. Boceprevir in Liver Transplant Recipients. EASL April 2014,
London, Great Britain.
64. Stepanova M, Hunt SL, Saab S, Frost S, Jeffers T, Younossi ZM. Outcomes of liver
transplantation in the United States: what has changed over the last 25 years? Digestive
Diseases Week. May 2014. Chicago, IL.
65. Choi G, Lee K, Wu C, Saab S. Renal transplantation threshold in patients with hepatitis
C liver fibrosis and cirrhosis: a decision analysis model. Digestive Diseases Week. May
2014. Chicago, IL.
66. Zhou K, Ferguson J, Elashoff D, Saab S. Treating chronic hepatitis C infection in the
elderly: estimated impact on life expectancy. Digestive Diseases Week. May 2014.
Chicago, IL.
67. Saab S, Manne V, Akhtar E. Cirrhosis regression in hepatitis C patients with sustained
virologic response after anti-viral therapy: a meta-analysis. Digestive Diseases Week.
May 2014. Chicago, IL.
68. Sundaram V, May FP, Manne V, Saab S. Clostridium difficile infection and acute
alcoholic hepatitis: the associated risk, mortality, and health care utilization. Digestive
Diseases Week. May 2014. Chicago, IL.
69. Gordon SC, Ahmed A, Saab S, Younossi Z. Evaluation of the Long-Term Health
Outcomes of Ledipasvir/Sofosbuvir (LDV/SOF) and Sofosbuvir-based Regimens for
Patients with Chronic Hepatitis C (CHC) And Liver Cirrhosis Across Genotypes 1 to 4
(GT 1-4): Results from a Decision-Analytic Markov Model. American Association for
the Study of Liver Diseases Annual Meeting November 2014, Boston, MA.
70. Ahmed A, Gordon SC, Saab S, Younossi Z. Evaluation of Health Outcomes for
Ledipasvir/Sofosbuvir in Early vs. Delaed Treatment According to Fibrosis Stage of
Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a
Decision-Analytic Markov Model. American Association for the Study of Liver Diseases
Annual Meeting November 2014, Boston, MA.
71. Younossi Z, Saab S, Ahmed A, Gordon SC. A Decision-Analytic Markov Model to
Evaluate the Health Outcomes of Ledipasvir/Sofosbuvir (LDV/SOF) for Patients with
Saab 60
Chronic Hepatitis C (HCV) Genotype 1 (GT1) Infection. American Association for the
Study of Liver Diseases Annual Meeting November 2014, Boston, MA.
72. Johnson SJ, Parise H, Virabhak S, Juday TR, Samp JC, Marx SE, Saab S. SVR Reduces
Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing
Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-
50/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment. European Association for
the Study of the Liver. April 2015, Vienna, Austria.
73. Johnson SJ, Samp JC, Juday TR, Marx SE, Parisé H, Virabhak C, Saab S. Reduction in
Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-
450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States. European
Association for the Study of the Liver. April 2015, Vienna, Austria.
74. Johnson S, Parise H, Sanchez Gonzalez Y, Wang A, S Virabhak S, Juday T, Saab S. The
Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with
All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting'. European Association
for the Study of the Liver. April 2015, Vienna, Austria.
75. Johnson SJ, Juday TR, Samp JC, Marx SE, Parisé H, Virabhak S, Saab S. Cost-
Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV)
With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin
Compared to No Treatment in the United States. European Association for the Study of
the Liver. April 2015, Vienna, Austria.
76. Lui A, Perumpail RB, Jayasekera CR, Tummala S, Saab S, Younossi ZM, Wong RJ,
Ahmed A. HCV Infection in Aging Baby Boomers is an Independent Predictor of Poor
Outcome in Liver Transplant Recipients: An Analysis of the UNOS Database. American
Association for the Study of Liver Diseases Annual Meeting November 2015, San
Francisco, CA.
77. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Quality-Adjusted
Cost of Care for Treatment Naïve (TN) Patients with Genotype 1 (GT1) Chronic
Hepatitis C (CH-C): An Assessment of Innovation Cost of Drug Regimens versus the
Value of Health Gains to the Society. American Association for the Study of Liver
Diseases Annual Meeting November 2015, San Francisco, CA.
78. Saab S, Virabhak S, Johnson SJ, Parisé H, Sanchez Y, Wang A, Juday TR. Lifetime risks
of liver morbidity and mortality in patients with chronic genotype (GT) 1 hepatitis c virus
(HCV) and HIV c coinfection treated with 3D±R (ombitasvir/paritaprevir/ritonavir,
dasabuvir ± ribavirin) vs other standards of care in the US. American Association for the
Study of Liver Diseases Annual Meeting November 2015, San Francisco, CA.
79. Szabo AM, Walker DR, Juday TR, Lane S, Saab S. Patient Reasons for Initiating or
Delaying Hepatitis C Virus (HCV) Treatment and Physician Reasons for Selecting an
HCV Treatment: A prospective Observational Study. American Association for the Study
of Liver Diseases Annual Meeting November 2015, San Francisco, CA.
80. Virabhak S, Johnson SJ, Parisé H, Juday TR, Wang A, Sanchez Y, Saab S. Cost-
effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir +/- ribavirin (3D±R) in
patients with genotype (GT) 1 chronic hepatitis C virus (HCV) and human
immunodeficiency virus (HIV) coinfection compared with other standards of care in the
US. American Association for the Study of Liver Diseases Annual Meeting November
2015, San Francisco, CA.
81. Saab S, Huber C, Wang A, Sanchez Y, Juday TR. Lifetime risks of liver morbidity and
mortality in patients with recurrent genotype 1 hepatitis C virus infection post-liver
transplantation treated with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin
Saab 61
(3D+R) vs former standards of care. American Association for the Study of Liver
Diseases Annual Meeting November 2015, San Francisco, CA.
82. Szabo SM, Walker DR, Juday TR, Lane S, Levy A, Saab S. Patient Expectations of the
Impact on Quality of Live of Hepatitis C Treatment. American Association for the Study
of Liver Diseases Annual Meeting November 2015, San Francisco, CA.
83. Saab S, Sanchez Y, Huber C, Wang A, Juday TR. The cost-effectiveness of
ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin (3D+R) in patients with liver
transplantation after genotype 1 hepatitis C virus infection. American Association for the
Study of Liver Diseases Annual Meeting November 2015, San Francisco, CA.
84. Patel AA, Shah O, Saab S, Sundaram V. The burden of osteoporotic hip and spine
fractures in elderly patients with cirrhosis. American Association for the Study of Liver
Diseases Annual Meeting November 2015, San Francisco, CA.
85. Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The Value of Cure
Associated with Treating Treatment-naïve (TN) Chronic Hepatitis C (CH-C) Genotype 1
(GT1): Are the New Oral Regimens a Good Value to Society? American Association for
the Study of Liver Diseases Annual Meeting November 2015, San Francisco, CA.
86. Perumpail RB, Liu A, Jayasekera CR, Marcus JH, Tummala S, Saab S, Younossi ZM.
An evidence-Based Algorithm to Optimize Patient Selection among Class III Obese
Liver Transplant Waitlist Registrants. American Association for the Study of Liver
Diseases Annual Meeting November 2015, San Francisco, CA.
87. Saab S, Gonzalez ST, Perumpail RB, Cholankeril G, Ahmed A, Younossi ZM. Cost
Effectiveness Analysis of Pre vs. Post LT Treatment with All Oral Direct Acting
Antivirals in Hepatitis C Patients with Decompensated Cirrhosis in the US. American
Association for the Study of Liver Diseases Annual Meeting November 2016. Boston,
MA.848. Presidential Poster of Distinction
88. Ahmed A, Saab S, Gordon SC, Dieterich DT, Wong RJ, Brown KA, Kugelmas M,
Younossi ZM. A Decision Analytic Markov Model to Evaluate the Health Outcomes of
Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotypes 1 to 6 and
Decompensated Cirrhosis in the US. American Association for the Study of Liver
Diseases Annual Meeting November 2016. Boston, MA.850. Presidential Poster of
Distinction
89. Younossi ZM, Gordon SC, Dieterich DT, Wong R, Brown KA, Kugelmas M, Saab S,
Ahmed A. A Decision Analytic Markov Model to Evaluate the Health Outcomes of
Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotype 1 infection
in the US. American Association for the Study of Liver Diseases Annual Meeting
November 2016. Boston, MA.856. Presidential Poster of Distinction
90. Gordon SC, Ahmed A, Kugelmas M, Dieterich DT, Wong R, Brown KA, Saab S,
Younossi ZM. A Decision Analytic Markov Model to Evaluate the Health Outcomes of
Sofosbuvir/Velpatasvir for Patients with Chronic Hepatitis C Virus Genotypes 2 and 3
Infection in the US. American Association for the Study of Liver Diseases Annual
Meeting November 2016. Boston, MA.858. Presidential Poster of Distinction.
91. Cholankeril G, Perumpail RB, Yoo ER, Hu M, Ahmed A, Saab S, Gonzalez SA,
Beckerman R. Direct-Acting Antiviral Therapy and Purgatory MELD: Fact or Fiction?
American Association for the Study of Liver Diseases Annual Meeting November 2016.
Boston, MA.859.
92. Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi ZM, Saab S, Ahmed A, Wong RJ.
Patients with Nonalcoholic Steatohepatitis Cirrhosis Are Significantly Less Likely to
Receive Appropriate Screening for Hepatocellular Carcinoma Compared to Patients with
Saab 62
Chronic Hepatitis C Virus Cirrhosis. American Association for the Study of Liver
Diseases Annual Meeting November 2016. Boston, MA.1299.
93. Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G,
Durazo FA, El-Kabany MM, Han SB, Saab S. Decrease of Alpha-Fetoprotein in Patients
with Cirrhosis Treated with Direct Acting Agents. Gastroenterology Updates in IBD &
Liver Disease, February 19 – 22, 2017, Maui, HI
94. Younossi Z, Stepanova M, Saab S, Hoyle KE, Cable R, Mishra A, Clement SC, Hunt SL.
Patients with Non-Alcoholic Steatohepatitis are at High Risk of Developing Post-
Transplant Diabetes. American Association for the Study of Liver Diseases Annual
Meeting November 2014, Boston, MA.
95. Nguyen K, Weber A, Choi G, Durazo FA, El-Kabany MM, Kang S, Saab S, Han SB.
Minimal monitoring in treating Hepatitis C with Direct Acting Antivirals.
Gastroenterology Updates in IBD & Liver Disease, February 19 – 22, 2017, Maui, HI
96. Nguyen K, Konyn P, Choi G, Durazo FA, Han SB, Ramirez S, Saab S, El-Kabany MM.
Lower sustained virologic response in patients with hepatocellular carcinoma treated for
hepatitis C with direct acting antivirals. Annual Meeting European Association for the
Study of Liver Diseases, April 19 – 23, 2017, Amsterdam, The Netherlands
97. Younossi ZM, Stepanova M, de Avila L, Ahmed A, Wong RJ, Saab S, Kowdley KV,
Brown KA, Kugelmas M, Racila A. Liver Transplant (LT) Candidates with Primary
Biliary Cholangitis (PBC) Experience Higher Wait List Mortality: Data from the
Scientific Registry of Transplant Recipients (SRTR). American Association for the Study
of Liver Diseases Annual Meeting October 2017, Washington DC.
98. Nguyen KT, Konyn P, Darwish T, Choi G, Durazo FA, Han SH, Ramirez S, Saab S, El-
Kabany MM. Lower sustained virologic response in patients with hepatocellular
carcinoma treated for hepatitis C with direct acting antivirals. American Association for
the Study of Liver Diseases Annual Meeting October 2017, Washington DC.
99. Gordon SC, Ahmed A, Saab S, Dieterich DT, Wong RJ, Kugelmas M, Brown KA,
Younossi ZM. Health Outcomes Associated with Sofosbuvir-based Single-Tablet
Regimens for Initial and Re-treatment of Chronic Hepatitis C in the US. American
Association for the Study of Liver Diseases Annual Meeting October 2017, Washington
DC.
100. Saab S, Parisé H, Virabhak S, Johnson S, Pinsky B, Sanchez Y. Pan-genotypic hepatitis
C treatment with glecaprevir/pibrentasvir achieves greatest improvements in quality-
adjusted life-years and lifetime risk reductions in liver-related morbidity and mortality vs
standards of care: a cost-utility analysis. American Association for the Study of Liver
Diseases Annual Meeting October 2017, Washington DC.
101. Aby E, Phan J, Saab S. The Impact of Inadequate HCC Screening in patients with NASH
Cirrhosis on Tumor Size. American Association for the Study of Liver Diseases Annual
Meeting October 2017, Washington DC.
102. Saab S, Alkhouri N, Allen L, Aggarwal K, Vredenburg M, Tian W, Terrault N. Efficacy
of Avatrombopag Compared with Placebo Across Various Mean Baseline Platelet Count
Subgroups- Pooled Data from 2 Phase III Studies. European Association for the Study of
the Liver Annual Meeting 2018, Paris, Francis.
103. Reau N, Saab S, Allen L, Aggarwal K, Vredenburg M, Kim R. Avatrombopag Decreases
Need for Platelet Transfusion in Patients with Chronic Liver Disease (CLD) and
Thrombocytopenia (TCP) Undergoing Medical Procedures with Low to High Associated
Bleeding Risks. European Association for the Study of the Liver Annual Meeting 2018,
Paris, Francis.
Saab 63
104. Yanny B, Saab S, Durazo F, Latt N, Mikhail M, Mitry A and Sahota A. Eight Week
Hepatitis C Treatment with New Direct Acting Agents Have a Better Safety Profile
While Effective in the Geriatric Population without Liver Cirrhosis and Hepatitis C
Virus-RNA <6 Million IU/Ml. American Association for the Study of Liver Diseases
Annual Meeting. November 2018. Abstract 696.
105. Patel A, Ryan G, Walling A, Chuang E, Cain C, Tran D, Gupta N, Wu T, Saab S,
Khemichian S, Sundaram V, Brook R, Wenger N. Advance Care Planning for Patients
with Decompensated Cirrhosis: Preliminary Results of a Multi-Center Qualitative Study.
American Association for the Study of Liver Diseases Annual Meeting. November 2018.
San Francisco, CA 2018. Abstract 764
106. Saab S, Saggi S, Akbar M, Choi G. Presumed Consent: A Potential Tool for Countries
Experiencing an Organ Donation Crisis. American Association for the Study of Liver
Diseases Annual Meeting. November 2018. Abstract. 1149B.
107. Reau N, Saab S. Allen LF, Aggarwal K, Vredenburg M, Kim R. Avatrombopag
Decreases Need for Platelet Transfusion in Patients with Chronic Liver Disease and
Thrombocytopenia Undergoing Medical Procedures with Low to High Associated
Bleeding Risks. Society of Interventional Radiology. Austin, TX March 23-28.
108. Wang Y, Lenhart A, Grewal J, Boutros S, Saleh F, Saab S, Yanny B. Liver
Transplantation for Alcoholic Hepatitis Offers the Best Survival Benefit: A Systematic
Review. Digestive Diseases Week. May 2020. Chicago, IL.
109. Wu E, Meneses KG, Kang S, Lee AK, Neogi S, Saab S. Marijuana Usage in Post-Liver
Transplant Recipients. Digestive Diseases Week. May 2020. Chicago, IL.
110. Winters AC, Viramontes MR, Buch A, Najarian L, Yum JJ, Yang L, Saab S. Less
Educated Patients with Hepatocellular Carcinoma are Not as Prepared for the
Survivorship Experience: Outcomes From a Survey-Based Study. Digestive Diseases
Week. May 2020. Chicago, IL.
111. Veracruz N, Hameed B, Saab S, Wong R. The Association between Nonalcoholic fatty
liver Disease and Risk of Cardiovascular Disease, stroke, and Extra-Hepatic Cancers: A
Systematic Review and Meta-Analysis. Digestive Diseases Week. May 2020. Chicago,
IL.
112. Perumpail RB, Khemichian S, Lakhoo K, Do A, Choi G, Durazo FA, EI-Kabany M,
Saab S, Busuttil RW, Han SH. Tenofovir Alafenamide for Hepatitis B Virus Prophylaxis
Post-Liver Transplantation is Associated with Improved Renal Function: A Multicenter
Real-World Experience. Digestive Diseases Week. May 2020. Chicago, IL.